<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Heliyon</journal-id><journal-id journal-id-type="iso-abbrev">Heliyon</journal-id><journal-id journal-id-type="pmc-domain-id">2992</journal-id><journal-id journal-id-type="pmc-domain">heliyon</journal-id><journal-title-group><journal-title>Heliyon</journal-title></journal-title-group><issn pub-type="epub">2405-8440</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11252876</article-id><article-id pub-id-type="pmcid-ver">PMC11252876.1</article-id><article-id pub-id-type="pmcaid">11252876</article-id><article-id pub-id-type="pmcaiid">11252876</article-id><article-id pub-id-type="pmid">39022002</article-id><article-id pub-id-type="doi">10.1016/j.heliyon.2024.e32357</article-id><article-id pub-id-type="pii">S2405-8440(24)08388-9</article-id><article-id pub-id-type="publisher-id">e32357</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Xu</surname><given-names initials="W">Wenhui</given-names></name><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Ye</surname><given-names initials="J">Jinghong</given-names></name><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Cao</surname><given-names initials="Z">Zhendong</given-names></name></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Zhao</surname><given-names initials="Y">Yupei</given-names></name></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Zhu</surname><given-names initials="Y">Yimin</given-names></name><email>efy037@njucm.edu.cn</email><xref rid="cor2" ref-type="corresp">&#8270;&#8270;</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Li</surname><given-names initials="L">Lei</given-names></name><email>efy112@njucm.edu.cn</email><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1">Department of Respiration, The Second Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (Jiangsu Second Hospital of Traditional Chinese Medicine), Nanjing, Jiangsu, 210017, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>efy112@njucm.edu.cn</email></corresp><corresp id="cor2"><label>&#8270;&#8270;</label>Corresponding author. <email>efy037@njucm.edu.cn</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0010">Co-first author: Wenhui Xu and Jinghong Ye.</p></fn></author-notes><pub-date pub-type="collection"><day>30</day><month>6</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>04</day><month>6</month><year>2024</year></pub-date><volume>10</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">465586</issue-id><elocation-id>e32357</elocation-id><history><date date-type="received"><day>22</day><month>3</month><year>2024</year></date><date date-type="rev-recd"><day>3</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>6</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>06</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>17</day><month>07</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-18 17:25:23.420"><day>18</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Authors. Published by Elsevier Ltd.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Glucocorticoids (GCs), a class of hormones secreted by the adrenal glands, are released into the bloodstream to maintain homeostasis and modulate responses to various stressors. These hormones function by binding to the widely expressed GC receptor (GR), thereby regulating a wide range of pathophysiological processes, especially in metabolism and immunity. The role of GCs in the tumor immune microenvironment (TIME) of lung cancer (LC) has been a focal point of research. As immunosuppressive agents, GCs exert a crucial impact on the occurrence, progression, and treatment of LC. In the TIME of LC, GCs act as a constantly swinging pendulum, simultaneously offering tumor-suppressive properties while diminishing the efficacy of immune-based therapies. The present study reviews the role and mechanisms of GCs in the TIME of LC.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Lung cancer</kwd><kwd>Tumor microenvironment</kwd><kwd>Glucocorticoids</kwd><kwd>Tumor immunity</kwd><kwd>Chronic airway inflammation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Composition and characteristics of tumor microenvironment (TME) in lung cancer (LC)</title><sec id="sec1.1"><label>1.1</label><title>Composition of TME in LC</title><p id="p0010">LC remains the leading cause of cancer mortality worldwide, with non-small cell LC (NSCLC) accounting for 80&#8211;85&#160;% of cases, where adenocarcinoma represents the predominant pathological type [<xref rid="bib1" ref-type="bibr">1</xref>]. Furthermore, the 5-year survival rate for patients with LC remains below 50&#160;%. The tumor immune microenvironment (TIME) prominently influences the robustness of anti-tumor immune responses through the spatial interactions among immune cells and between immune cells and other cell types [<xref rid="bib2" ref-type="bibr">2</xref>]. These interactions are critically linked to tumor progression and the prognosis of LC, underscoring the importance of TIME in the therapeutic landscape [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib4" ref-type="bibr">4</xref>].</p><sec id="sec1.1.1"><label>1.1.1</label><title>Role of tumor cells in TME</title><p id="p0015">Tumor cells constitute the core component of the TME in LC, characterized by autonomous growth, unrestricted division, and evasion of immune surveillance [<xref rid="bib5" ref-type="bibr">5</xref>]. LC cells can be categorized into several histological types, such as adenocarcinoma, squamous cell carcinoma, and small-cell LC [<xref rid="bib6" ref-type="bibr">6</xref>]. These different types of tumor cells exhibit variations in gene expression, signaling pathways, and sensitivity to treatment. The tumor has been studied as a complex organ, indicating that the tumor constituents (tumor cells) are not inherently malignant. Instead, they require the involvement of the tumor stroma (non-tumor cells) to facilitate tumorigenesis, including continuous inflammation [<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib8" ref-type="bibr">8</xref>]. In their initial stages, tumor cells guide the formation of vasculature in the TME to recruit nutrients, cell-derived vesicles, and immune cells, thereby facilitating the development of many cancer characteristics [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>].</p></sec><sec id="sec1.1.2"><label>1.1.2</label><title>Role of immune cells in TME</title><p id="p0020">Immune cells, comprising both innate and adaptive immune cells, exert a critical regulatory influence on the TME, which is essential in the tumorigenesis, development, and treatment of tumors [<xref rid="bib11" ref-type="bibr">11</xref>,<xref rid="bib12" ref-type="bibr">12</xref>]. Innate immune cells mainly include dendritic cells (DCs), macrophages, and myeloid-derived suppressor cells (MDSCs) [<xref rid="bib13" ref-type="bibr">13</xref>]. Their primary function in the TME is to recognize pathogens and tumor-associated antigens, thereby activating the adaptive immune response [<xref rid="bib14" ref-type="bibr">14</xref>]. DCs, as essential initiators of the immune response, capture and present tumor-associated antigens to activate adaptive immune cells such as CD8<sup>+</sup> T cells [<xref rid="bib15" ref-type="bibr">15</xref>]. Macrophages have a dual role in the TME, and they are capable of eliminating tumor cells while potentially augmenting tumor growth [<xref rid="bib16" ref-type="bibr">16</xref>]. MDSCs, by secreting various suppressive molecules, repress the function of immune cells and affect the outcomes of tumor immune responses [<xref rid="bib17" ref-type="bibr">17</xref>].</p><p id="p0025">Adaptive immune cells primarily include CD8<sup>+</sup> T cells and regulatory T cells (Tregs) [<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib19" ref-type="bibr">19</xref>]. CD8<sup>+</sup> T cells, as the primary effector cells in the anti-tumor immune response, recognize and eliminate tumor cells [<xref rid="bib20" ref-type="bibr">20</xref>]. However, their functional activity is notably diminished in the TME, undermining the efficacy of the immune response against tumors [<xref rid="bib21" ref-type="bibr">21</xref>]. Meanwhile, Tregs impart immunosuppressive effects in the TME, curbing the immune response through suppressive cytokines or direct interaction with immune cells [<xref rid="bib22" ref-type="bibr">22</xref>]. The critical involvement of Tregs in facilitating tumor immune evasion makes the reduction of Treg activity or blockade of their function a focal point of research in tumor immunotherapy [<xref rid="bib23" ref-type="bibr">23</xref>]. In summary, the regulatory role of immune cells in the TME is indispensable, highlighting its potential as a therapeutic target in the ongoing battle against cancer.</p></sec><sec id="sec1.1.3"><label>1.1.3</label><title>Role of extracellular matrix (ECM) in TME</title><p id="p0030">The ECM, another critical component of the TME, comprises various proteins such as fibronectin, elastin, and matrix metalloproteinases (MMPs) [<xref rid="bib24" ref-type="bibr">24</xref>]. The ECM provides physical support to tumor cells and actively participates in signaling, cell migration, and angiogenesis [<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib26" ref-type="bibr">26</xref>]. In LC, abnormal expression and distribution of ECM are closely associated with tumor progression and an unfavorable prognosis [<xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib28" ref-type="bibr">28</xref>]. The proteins in the ECM can be categorized into fibrillar proteins (fibronectin, collagen, laminin, and elastin) and glycosaminoglycans (chondroitin sulfate, hyaluronic acid, heparan sulfate, and keratan sulfate) [<xref rid="bib29" ref-type="bibr">29</xref>]. Through crosslinking mechanisms, these molecules are distributed abundantly in the ECM, contributing to the formation of a net-like tissue structure crucial for providing mechanical support to tumor cells [<xref rid="bib30" ref-type="bibr">30</xref>]. Additionally, they are implicated in intercellular communication, cell proliferation, and metastasis [<xref rid="bib31" ref-type="bibr">31</xref>]. ECM, as a pivotal component of the TME, undergoes continuous remodeling, and ECM stiffening is a notable characteristic of tumors [<xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>]. In a stiffened ECM, the deposition of collagen and hyaluronic acid leads to high solid stress within the tumor, causing vascular collapse. This condition results in insufficient perfusion of tumor tissue, inhibits immune cell infiltration, and hinders drug delivery and distribution. ECM stiffening can induce the activation of certain ion channels and cell signaling pathways, ultimately influencing tumor growth, angiogenic potential, metastatic capacities, immune escape, and resistance to therapeutic agents [<xref rid="bib35" ref-type="bibr">35</xref>].</p><p id="p0035">During tumor progression, immune cells respond to signals from the ECM. ECM stiffening inhibits the perivascular infiltration of T cells, causing them to migrate along the ECM-rich tumor capsule [<xref rid="bib37" ref-type="bibr">36</xref>,<xref rid="bib38" ref-type="bibr">37</xref>]. This phenomenon, observed in various cancers, such as colorectal cancer and LC, can adversely affect the immune response [<xref rid="bib39" ref-type="bibr">38</xref>]. ECM stiffening also leads to hypoxia, induces glycolytic metabolism, creates an acidic environment, and inhibits the activation of T lymphocytes [<xref rid="bib40" ref-type="bibr">39</xref>]. Concurrently, it increases the production of immunosuppressive mediators such as transforming growth factor-beta (TGF-&#946;), affecting Treg differentiation, promoting abnormal angiogenesis, and diminishing the expression of cell adhesion molecules and surface glycoproteins [<xref rid="bib41" ref-type="bibr">40</xref>]. This further impacts the infiltration of T cells [<xref rid="bib42" ref-type="bibr">41</xref>]. Additionally, ECM components regulate macrophage polarization, with studies reporting that collagen and hyaluronic acid can drive macrophage M1 polarization <italic toggle="yes">in vitro</italic> [<xref rid="bib43" ref-type="bibr">42</xref>,<xref rid="bib44" ref-type="bibr">43</xref>]. Collectively, ECM modulation can enhance the effectiveness of anti-tumor therapy by regulating the TME, improving drug permeability, and enhancing the immune response, thereby providing new opportunities for the development of personalized treatment strategies.</p></sec><sec id="sec1.1.4"><label>1.1.4</label><title>Dynamics of angiogenesis in tumor progression</title><p id="p0040">Angiogenesis in the tumor context is crucial for the sustained survival and proliferation of cancer cells, critically influencing their ability to grow, invade, and metastasize [<xref rid="bib45" ref-type="bibr">44</xref>]. The TME, composed of tumor cells, adjacent cellular entities, and a milieu of secreted cytokines, orchestrates a favorable setting for oncogenic growth and survival [<xref rid="bib46" ref-type="bibr">45</xref>]. The interplay of multiple factors in the TME imparts critical effects on shaping tumor development [<xref rid="bib47" ref-type="bibr">46</xref>]. This review provides insights into the regulatory influence of the microenvironment on the angiogenic process in tumors. The pronounced expression of angiogenic factors and inflammatory cytokines, coupled with hypoxic environments in the TME, underscores the unfavorable effectiveness of existing anti-angiogenic medications [<xref rid="bib48" ref-type="bibr">47</xref>]. Strategic combinations of anti-angiogenic agents with drugs targeting tumor-promoted inflammation or hypoxia may enhance therapeutic efficacy [<xref rid="bib49" ref-type="bibr">48</xref>].</p><p id="p0045">Tumor angiogenesis also affects the TME, enabling cancer cells to migrate along the walls of newly formed vessels and initiating the growth and the genesis of new tumors at specific sites [<xref rid="bib50" ref-type="bibr">49</xref>]. Tumor angiogenesis triggers immune suppression in the TME through various mechanisms, including the repression of DC maturation and antigen presentation, recruitment of immunosuppressive cells, and suppression of cytotoxic T cell function mediated by angiogenic factors [<xref rid="bib51" ref-type="bibr">50</xref>]. Furthermore, tumor-induced neovascularization is characterized by immature development, wherein inadequate adhesion of endothelial cells results in excessive vascular permeability, poor perfusion, and minimal amelioration of hypoxia [<xref rid="bib52" ref-type="bibr">51</xref>]. The escalation of hypoxia in solid tumors further intensifies both tumor growth and metastatic potential [<xref rid="bib53" ref-type="bibr">52</xref>]. Concurrently, the TME promotes the production of numerous factors that enhance tumor angiogenesis, thereby creating a vicious cycle of malignant tumor growth [<xref rid="bib54" ref-type="bibr">53</xref>].</p></sec><sec id="sec1.1.5"><label>1.1.5</label><title>Role of cancer-associated fibroblasts (CAFs) in the TME</title><p id="p0050">CAFs play crucial roles in the TME, influencing tumor initiation, progression, and treatment outcomes through interactions with cancer cells, matrix components, and immune cells [<xref rid="bib55" ref-type="bibr">54</xref>]. The interplay between CAFs and tumor cells facilitates tumor development through various pathways. On the one hand, CAFs can secrete a multitude of cytokines, growth factors, and chemokines <italic toggle="yes">via</italic> paracrine actions, thereby stimulating tumor cell proliferation, invasion, and metastasis [<xref rid="bib56" ref-type="bibr">55</xref>]. On the other hand, CAFs can adhere to tumor cells through direct contact, influencing tumor cell growth and differentiation [<xref rid="bib57" ref-type="bibr">56</xref>].</p><p id="p0055">In the context of TME remodeling, CAFs assume a central role by secreting various proteases, such as MMPs, to degrade ECM components, thereby promoting tumor cell invasion and metastasis [<xref rid="bib58" ref-type="bibr">57</xref>]. Additionally, CAFs can alter the structure and function of the ECM by secreting enzymes like fibrinolysins and collagenases, creating favorable conditions for tumor cell growth [<xref rid="bib59" ref-type="bibr">58</xref>,<xref rid="bib60" ref-type="bibr">59</xref>].</p><p id="p0060">CAFs are key players in tumor angiogenesis, releasing pro-angiogenic molecules such as vascular endothelial growth factor (VEGF) to foster the development of tumor vasculature [<xref rid="bib61" ref-type="bibr">60</xref>]. Simultaneously, CAFs interact directly with endothelial cells to promote their migration and proliferation, thus further driving tumor angiogenesis [<xref rid="bib62" ref-type="bibr">61</xref>]. Cancer cells can evade host immune surveillance through various mechanisms to achieve immune escape [<xref rid="bib63" ref-type="bibr">62</xref>]. CAFs play a key role in this process [<xref rid="bib64" ref-type="bibr">63</xref>,<xref rid="bib65" ref-type="bibr">64</xref>]. They can secrete immunosuppressive factors, such as TGF-&#946; and prostaglandin E2 (PGE2) [<xref rid="bib66" ref-type="bibr">65</xref>,<xref rid="bib67" ref-type="bibr">66</xref>], which impair immune cell function and facilitate the recruitment of immunosuppressive cells, thereby diminishing the effectiveness of tumor immunotherapy [<xref rid="bib68" ref-type="bibr">67</xref>].</p></sec></sec><sec id="sec1.2"><label>1.2</label><title>Combined immunotherapy tailored to TME complexity</title><p id="p0065">Tumors can be broadly classified into hot, cold, immunosuppressive, and excluded phenotypes based on TME characteristics. Hot tumors exhibit pronounced T cell infiltration and PD-L1 expression, rendering them particularly responsive to PD-1/PD-L1 blockade therapies [<xref rid="bib69" ref-type="bibr">68</xref>]. In contrast, cold tumors demonstrate diminished tumor mutational burden (TMB), limited T cell infiltration, and reduced expression levels of major histocompatibility complex (MHC) and PD-L1 [<xref rid="bib70" ref-type="bibr">69</xref>]. Consequently, alternative therapeutic strategies such as chimeric antigen receptor T-cell (CAR-T) therapy, radiotherapy, and chemotherapy have become imperative to achieve desired treatment outcomes. Immunosuppressive tumors, characterized by a moderate number of infiltrating T cells, engage in immune evasion through the secretion of immunosuppressive molecules, including interleukin (IL)-10, TGF-&#946;, and the recruitment of Tregs and tumor-associated macrophages (TAMs). Further, they involve the presence of immune checkpoints such as T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) and lymphocyte-activation gene 3 (LAG3) [<xref rid="bib71" ref-type="bibr">70</xref>]. Excluded tumors feature an accumulation of T cells and other effector cells at their invasive margins, forming a natural barrier that prevents effective infiltration into the tumor mass [<xref rid="bib72" ref-type="bibr">71</xref>,<xref rid="bib73" ref-type="bibr">72</xref>]. Therapeutic strategies, such as anti-angiogenesis, aim to remodel the peri-tumoral microenvironment, thereby enhancing the penetration and efficacy of therapeutic interventions [<xref rid="bib74" ref-type="bibr">73</xref>]. Details are shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>.<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Combined immunotherapy tailored to the complexity of the TME. Tumors can be broadly categorized based on the characteristics of their microenvironment into hot, cold, immunosuppressive, and excluded tumors. Hot tumors exhibit prominent features such as extensive infiltration by T cells, elevated levels of PD-L1, increased TMB, and enhanced gamma-interferon signaling. Therapeutic approaches include <italic toggle="yes">ex vivo</italic> expanded and adoptively transferred tumor-infiltrating lymphocytes (TIL-ACT) and chemotherapy. Cold tumors, characterized by scant T cell presence, low TMB, and diminished MHC and PD-L1 expression, may benefit from interventions like CAR-T therapy, radiation, and chemotherapy. Immunosuppressive tumors present with moderate T cell infiltration but are marked by a TME that hinders additional immune cell recruitment and activation. Tumor cells achieve immune escape by releasing IL-10 and TGF-&#946;, recruiting Tregs and TAMs, with immune checkpoints such as TIGIT and LAG3 playing pivotal roles. Excluded tumors are characterized by the aggregation of T cells and other effector cells at the invasive margin, unable to effectively infiltrate into the tumor core. Tumor cells form a stromal barrier, which facilitates angiogenesis and embeds into an immunosuppressive microenvironment characterized by hypoxia and metabolic deprivation. Therapeutic strategies, including the targeting of VEGFA with specific antibodies, aim to dismantle these barriers and modulate the tumor microenvironment to restore immune surveillance and enhance anti-tumor responses.</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec></sec><sec id="sec2"><label>2</label><title>GC production by tumor cells and its role in immunosuppression</title><sec id="sec2.1"><label>2.1</label><title>Immunosuppressive microenvironment formed by tumor cells</title><p id="p0070">Conventionally, TME is recognized for harboring cells exhibiting immunosuppressive properties, and the resistance observed towards immune checkpoint inhibitors (ICIs) in cancer has been closely linked to this particular attribute [<xref rid="bib75" ref-type="bibr">[74]</xref>, <xref rid="bib76" ref-type="bibr">[75]</xref>, <xref rid="bib77" ref-type="bibr">[76]</xref>]. Tregs, MDSCs, and M2 phenotype TAMs foster the suppression of immune responses through a cytokine network, thereby inducing immunosuppression [<xref rid="bib78" ref-type="bibr">77</xref>]. Tregs exert their suppressive effects on T cell responses through diverse mechanisms, and their association with adverse clinical outcomes is commonly observed in individuals with LC [<xref rid="bib79" ref-type="bibr">78</xref>]. In a recent study evaluating patients with NSCLC and those with other solid tumors, a marked increase in the proportion of PD-1<sup>+</sup> Tregs among patients refractory to PD-1/PD-L1 blockade therapies was observed [<xref rid="bib80" ref-type="bibr">79</xref>]. This investigation underscores the significance of evaluating the balance of PD-1 expression between CD8<sup>+</sup> T cells and Tregs in the TME as a potentially more accurate predictor of the clinical response to ICI therapy than conventional markers such as PD-L1 expression or TMB. Although anti-PD-1/PD-L1 ICIs exhibit efficacy in reinvigorating dysfunctional PD-1<sup>+</sup> CD8<sup>+</sup> T cells, they also have the propensity to intensify immunosuppressive activity mediated by PD-1<sup>+</sup> Tregs. A prior investigation involving 73 NSCLC patients who underwent treatment with anti-PD-1/PD-L1 ICIs highlighted the significance of PD-L1<sup>+</sup> Tregs in the TME as a supplementary predictive biomarker for ICI responsiveness. Therefore, targeting Tregs presents a promising avenue for augmenting the therapeutic effectiveness of ICIs in LC [<xref rid="bib81" ref-type="bibr">80</xref>].</p><p id="p0075">MDSCs orchestrate a multifaceted immunosuppressive condition in the TME through several mechanisms: (i) the production of nitric oxide (NO) and reactive oxygen species (ROS); (ii) depletion of crucial nutrients, including <sc>l</sc>-arginine and <sc>l</sc>-tryptophan, essential for T cells; iii) disruption of T cell homing and transport; (iv) induction of checkpoint upregulation; and (v) secretion of immunoregulatory molecules such as adenosine, VEGF-&#945;, and inhibitory cytokines (IL-10) [<xref rid="bib82" ref-type="bibr">81</xref>]. MDSCs, similar to Tregs, express the ectonucleotidases CD39 and CD73, converting ATP to adenosine, which is considered a key mediator of immunosuppression in the TME [<xref rid="bib83" ref-type="bibr">82</xref>]. MDSCs expressing CD39 and CD73 have been detected in tumor tissues of NSCLC patients, with their expression positively associated with disease progression [<xref rid="bib84" ref-type="bibr">83</xref>]. However, chemotherapy interventions significantly reduce the abundance of these cells. The involvement of MDSCs in the progression of LC and resistance to ICI therapy has been extensively investigated using preclinical mouse models [<xref rid="bib85" ref-type="bibr">[84]</xref>, <xref rid="bib86" ref-type="bibr">[85]</xref>, <xref rid="bib87" ref-type="bibr">[86]</xref>]. These investigations have underscored the significant role of MDSCs in promoting LC metastasis, highlighting the potential of MDSC inhibition as a strategy to circumvent resistance to ICIs.</p><p id="p0080">The investigation into the impact of TAMs in an NSCLC patient cohort highlighted the presence of CD163<sup>+</sup> CD33<sup>+</sup> PD-L1<sup>+</sup> TAMs of M2 phenotype in highly progressive disease states, characterized by their epithelioid (alveolar macrophage-like) morphology and propensity to cluster within neoplastic lesions [<xref rid="bib88" ref-type="bibr">87</xref>]. In 33 stage II&#8211;IV NSCLC patients receiving ICI therapy, low levels of CD8<sup>+</sup> PD-L1<sup>+</sup> T cells and CD68<sup>+</sup> CD163<sup>+</sup> TAMs of the M2 phenotype predicted a positive response [<xref rid="bib89" ref-type="bibr">88</xref>]. Based on DNA-based quantitative immunofluorescence and confocal microscopy, the predominant PD-L1<sup>+</sup> cell population was identified as CD68<sup>+</sup> macrophages. In a cohort of 81 patients receiving anti-PD-1 therapy (YTMA404 cohort), an elevated presence of PD-L1<sup>+</sup> CD68<sup>+</sup> macrophages in the TME was linked to enhanced overall survival (OS) [<xref rid="bib90" ref-type="bibr">89</xref>].</p><p id="p0085">Kargl et al. identified a negative association between the abundance of neutrophils in the TME and the presence of CD8<sup>+</sup> and CD4<sup>+</sup> T cells, including Th1 and Th17 subsets, but found no correlation with Treg. This finding suggests a potential immunosuppressive function of neutrophils in NSCLC [<xref rid="bib91" ref-type="bibr">90</xref>,<xref rid="bib92" ref-type="bibr">91</xref>]. In preclinical investigations using IL-17:K-Ras mutant transgenic mice, the depletion of neutrophils was elucidated to eliminate resistance to PD-1 therapy, thereby restoring T cell activation [<xref rid="bib93" ref-type="bibr">92</xref>]. The involvement of neutrophils in conferring resistance to ICI therapy in patients with NSCLC remains to be clarified.</p><p id="p0090">Exploration of the tumor immunosuppressive microenvironment is pivotal for elucidating tumor immune evasion mechanisms and identifying novel targets for immunotherapeutic interventions. Treatments aimed at modulating the tumor immunosuppressive microenvironment, including ICIs and CAR-T therapy, have shown remarkable clinical success [<xref rid="bib95" ref-type="bibr">93</xref>]. Nonetheless, the inherent complexity of the tumor immunosuppressive landscape continues to pose significant challenges for the development of targeted therapies, particularly in terms of enhancing treatment efficacy and minimizing adverse effects [<xref rid="bib96" ref-type="bibr">94</xref>].</p></sec><sec id="sec2.2"><label>2.2</label><title>GC production by tumor cells and its immunomodulatory effects</title><p id="p0095">GCs, hormones synthesized by the adrenal glands, are released into the bloodstream to maintain homeostasis and regulate the body's response to various stressors [<xref rid="bib97" ref-type="bibr">95</xref>,<xref rid="bib98" ref-type="bibr">96</xref>]. These hormones exert their effects through interaction with the GC receptor (GR), which is ubiquitously expressed across various cell types, thereby influencing a broad spectrum of pathophysiological pathways with pronounced impacts on metabolism and immunity [<xref rid="bib99" ref-type="bibr">97</xref>]. The suppressive effect of GCs on T cell functionality is well established [<xref rid="bib100" ref-type="bibr">98</xref>,<xref rid="bib101" ref-type="bibr">99</xref>]. For instance, the deletion of the GR in T cells infected with <italic toggle="yes">Toxoplasma gondii</italic> leads to extensive cytokine secretion, resulting in the death of the mice [<xref rid="bib102" ref-type="bibr">100</xref>]. GCs not only suppress the antigen presentation and cytokine secretion functions of DCs but also curtail the differentiation of helper T cells and compromise T cell function [<xref rid="bib103" ref-type="bibr">101</xref>]. Recent studies have also demonstrated that GCs suppress immunity by affecting the function of Tregs [<xref rid="bib104" ref-type="bibr">102</xref>].</p><p id="p0100">Adrenal cells can process cholesterol into GCs through a novel synthetic pathway involving various mitochondrial and microsomal enzymes [<xref rid="bib105" ref-type="bibr">103</xref>]. P450c11&#946; (encoded by <italic toggle="yes">Cyp11b1</italic>) is the final enzyme in this conversion process, capable of transforming steroid precursors into active GCs (cortisol in humans, corticosterone in mice) [<xref rid="bib106" ref-type="bibr">104</xref>]. GCs are metabolized in the kidneys and colon into inactive forms&#8212;cortisone in humans and dehydrocorticosterone (DHC) in mice&#8212;by 11&#946;HSD2 (encoded by <italic toggle="yes">Hsd11b2</italic>) [<xref rid="bib107" ref-type="bibr">105</xref>]. These inactive metabolites are transported <italic toggle="yes">via</italic> the bloodstream and can be converted back into active GCs under the influence of 11&#946;HSD1 (encoded by <italic toggle="yes">Hsd11b1</italic>) through a recycling pathway [<xref rid="bib108" ref-type="bibr">106</xref>]. 11&#946;HSD1 is predominantly expressed in the liver but is also present in adipose tissues, the brain, and lymphoid organs [<xref rid="bib109" ref-type="bibr">107</xref>]. In addition to the adrenal glands, other organs can synthesize GCs, especially in sites prone to immune activation, such as the thymus, intestines, and skin [<xref rid="bib110" ref-type="bibr">108</xref>]. Compared with systemic administration of GCs, its local synthesis and secretion not only suppress immunity but also avoid the side effects associated with systemic administration [<xref rid="bib111" ref-type="bibr">109</xref>]. Local synthesis often occurs in cells that are highly proliferative and mutation-prone. Therefore, it is plausible that tumor cells themselves may synthesize GCs, thereby suppressing the anti-tumor immunity of immune cells [<xref rid="bib112" ref-type="bibr">110</xref>].</p></sec></sec><sec id="sec3"><label>3</label><title>Mechanistic pathways of GC action in tumor cells</title><p id="p0105">The intricate molecular mechanisms underlying the actions of GCs constitute a critical foundation for refining their clinical applications [<xref rid="bib113" ref-type="bibr">111</xref>]. These mechanisms can be categorized into genomic and non-genomic pathways, where the classic genomic mechanism involves mediation by cytoplasmic GC receptor &#945; (cGCR&#945;) [<xref rid="bib114" ref-type="bibr">112</xref>]. The non-genomic mechanisms encompass three types [<xref rid="bib115" ref-type="bibr">113</xref>]: (i) cGCR-mediated non-genomic mechanisms; (ii) specific non-genomic mechanisms, such as physicochemical interactions with the plasma membrane at elevated GC concentrations; and (iii) membrane GCR-mediated mechanisms.</p><sec id="sec3.1"><label>3.1</label><title>Canonical cGCR-mediated genomic mechanism</title><p id="p0110">The cGCR is a complex multiprotein structure in the majority of cells in the body [<xref rid="bib116" ref-type="bibr">114</xref>]. This receptor complex comprises various heat shock proteins (Hsps), such as Hsp40, Hsp70, Hsp90, and Hsp56 [<xref rid="bib117" ref-type="bibr">115</xref>]. Additionally, the cGCR interacts with immunophilins, co-chaperones such as p23 and Src, and kinases involved in the mitogen-activated protein kinase (MAPK) pathway [<xref rid="bib118" ref-type="bibr">116</xref>]. GCs, belonging to a group of glucocorticosteroids (GCSs) characterized by their lipophilic nature, enable easy diffusion across cell membranes [<xref rid="bib119" ref-type="bibr">117</xref>]. Upon binding to the cGCR, GCs initiate the activation of the GC-cGCR, which in turn coordinates gene transcription [<xref rid="bib120" ref-type="bibr">118</xref>]. Concurrently, chaperone proteins associated with the cGCR undergo translocation into the cytoplasm. Following a 20-min binding, the activated GC-cGCR complex is transported to the nucleus, where its binding to distinct DNA sites modulates processes of transcription and translation in the nucleus [<xref rid="bib121" ref-type="bibr">119</xref>]. Certain genes are upregulated to enhance the production of anti-inflammatory proteins, whereas the expression of genes responsible for generating pro-inflammatory mediators is suppressed, leading to immunosuppressive effects [<xref rid="bib122" ref-type="bibr">120</xref>]. However, GCSs typically take several hours or days to diffuse to the cell membrane, bind to cGCRs, transport the resulting GC-cGCR complex to the nucleus, interact with target gene promoter regions, and initiate transcription and translation processes leading to protein synthesis [<xref rid="bib123" ref-type="bibr">121</xref>]. Hence, the rapid manifestation of anti-inflammatory and anti-allergic effects elicited by GCSs cannot be solely attributed to the conventional genomic mechanism.</p></sec><sec id="sec3.2"><label>3.2</label><title>Non-genomic mechanisms of GCSs</title><p id="p0115">The rapid anti-inflammatory and immunosuppressive reactions elicited by GCSs can be attributed to three principal non-genomic pathways [<xref rid="bib124" ref-type="bibr">122</xref>,<xref rid="bib125" ref-type="bibr">123</xref>]: (i) Non-specific interactions between GCSs and the cell membrane. Elevated concentrations of GCSs can directly permeate the cell membrane, modifying the physicochemical properties and activities of membrane-bound proteins. This alteration results in diminished calcium and sodium transport across the membranes of immune cells, facilitating rapid immunosuppression. (ii) Non-genomic actions orchestrated by the cGCR. The unbound cGCR engages in a complex interplay involving ligands like Src, Hsps, and signaling molecules. Upon GC binding, these constituents are released, eliciting immediate immunosuppressive effects. (iii) Non-genomic effects mediated by membrane-bound GCR (mGCR). mGCR is present on the surface of immune cells, and upon binding with GCs, it leads to the rapid onset of non-genomic immunomodulatory effects.</p></sec><sec id="sec3.3"><label>3.3</label><title>Impact of GCSs on the immune system responses</title><p id="p0120">The activation of T cell functions by ICIs can lead to a series of inflammatory adverse events, the precise pathophysiological mechanisms of which are not fully understood [<xref rid="bib126" ref-type="bibr">124</xref>]. Current understanding suggests that immune-related adverse events (irAEs) may arise through various pathways involving autoreactive T cells, autoantibodies, and cytokines [<xref rid="bib127" ref-type="bibr">125</xref>]. ICIs are thought to cause abnormal activation of T lymphocytes, with irAEs primarily resulting from the immune attack by these activated T lymphocytes, as substantiated through pathological biopsies in myocarditis, pneumonitis, skin toxicity, and other types of irAEs [<xref rid="bib128" ref-type="bibr">126</xref>]. Consequently, GCSs are considered a first-line treatment option [<xref rid="bib129" ref-type="bibr">127</xref>,<xref rid="bib130" ref-type="bibr">128</xref>]. GCSs possess anti-inflammatory and immunosuppressive properties, capable of mitigating the damage caused by immune attacks and alleviating symptoms associated with irAEs [<xref rid="bib131" ref-type="bibr">129</xref>].</p><p id="p0125">GCs, pivotal in mediating anti-inflammatory and immunosuppressive responses, are classified into endogenous and exogenous categories, each playing a vital role in physiological and therapeutic contexts [<xref rid="bib132" ref-type="bibr">130</xref>]. Endogenously produced GCs provide basal anti-inflammatory effects, with an escalated secretion in response to inflammatory challenges [<xref rid="bib133" ref-type="bibr">131</xref>]. Hence, animals and humans with adrenal insufficiency demonstrate amplified responses to minor injuries post-adrenalectomy [<xref rid="bib134" ref-type="bibr">132</xref>,<xref rid="bib135" ref-type="bibr">133</xref>]. This observation has prompted speculation regarding the potential role of insufficient GC secretion in response to trauma or infection in the pathogenesis of select chronic inflammatory disorders [<xref rid="bib136" ref-type="bibr">134</xref>,<xref rid="bib137" ref-type="bibr">135</xref>]. Exogenously administered GCs demonstrate remarkable efficacy as anti-inflammatory agents to impede the functions of both the innate and adaptive immune systems [<xref rid="bib138" ref-type="bibr">136</xref>]. Both endogenously produced and externally administered GCs exhibit effectiveness in addressing inflammatory responses [<xref rid="bib139" ref-type="bibr">137</xref>]. They can attenuate nearly all manifestations of inflammation, regardless of whether they are triggered by invading pathogens, chemical or physical agents, or aberrant immune reactions such as hypersensitivity or autoimmune conditions [<xref rid="bib140" ref-type="bibr">138</xref>]. GCs are more effective in restricting the initiation and progression of immune responses when used prophylactically to inhibit transplant rejection than in preventing already initiated clonal proliferation responses [<xref rid="bib141" ref-type="bibr">139</xref>,<xref rid="bib142" ref-type="bibr">140</xref>]. They can also alter gene expression, given the capacity of GCs to modulate the expression of numerous genes, influencing approximately 1&#160;% of the total genome. With the pattern and extent of GC-mediated gene expression varying between tissues and even at different stages of the disease, their impact is significant and wide-ranging [<xref rid="bib143" ref-type="bibr">[141]</xref>, <xref rid="bib144" ref-type="bibr">[142]</xref>, <xref rid="bib145" ref-type="bibr">[143]</xref>].</p><p id="p0130">GCSs target several primary and secondary inflammatory cells, dampening the activation, proliferation, differentiation, and viability of diverse inflammatory cell subsets, including T lymphocytes and macrophages [<xref rid="bib146" ref-type="bibr">144</xref>]. Furthermore, GCSs facilitate apoptosis through the modulation of cytokine production, particularly triggering apoptosis in immature and activated T lymphocytes [<xref rid="bib147" ref-type="bibr">145</xref>]. They do not induce a notable acute alteration in the count of circulating B lymphocytes, and no studies have offered evidence indicating any impact of GCSs on IgM levels [<xref rid="bib148" ref-type="bibr">146</xref>,<xref rid="bib149" ref-type="bibr">147</xref>]. GCSs exhibit a slight capacity to induce neutrophil activation. Furthermore, GCSs can curb the generation of adhesion molecules to diminish endothelial cell adhesion and lower vascular permeability, thus reducing inflammatory exudation [<xref rid="bib150" ref-type="bibr">148</xref>]. Supraphysiological concentrations of GCSs demonstrate the capacity to restrain fibroblast proliferation and attenuate the production of IL-1 and tumor necrosis factor (TNF)-&#945;, demonstrating their effective anti-inflammatory action [<xref rid="bib151" ref-type="bibr">149</xref>]. The effects on inflammatory cells include: (i) reducing the number of neutrophils in the blood, lowering the activation of neutrophils, macrophages, and mast cells, which is secondary to the inhibition of cell adhesion molecule and cytokine gene transcription [<xref rid="bib152" ref-type="bibr">150</xref>]; (ii) lowering the overall activation rate of helper T (Th) cells, reducing T cell clonal proliferation, and initiating the transition from Th1-type immune response to Th2-type immune response [<xref rid="bib153" ref-type="bibr">151</xref>]; (iii) reducing the functionality of fibroblasts, decreasing the production of collagen and glycosaminoglycans, and in some cases, reducing healing and repair capabilities [<xref rid="bib154" ref-type="bibr">152</xref>].</p><p id="p0135">The effects of GCSs on mediators of inflammation and immune responses include: (i) reducing the production of prostaglandin compounds by decreasing the expression of cyclooxygenase II and inhibiting the release of arachidonic acid substrates [<xref rid="bib155" ref-type="bibr">153</xref>]; (ii) decreasing the production of numerous cytokines, including TNF-&#945;, cell adhesion molecules, IL-1, IL-3, IL-2, IL-4, IL-6, IL-5, IL-8, and granulocyte-macrophage colony-stimulating factor, largely secondary to the inhibition of gene transcription [<xref rid="bib156" ref-type="bibr">154</xref>]; (iii) lowering the concentration of complement components in plasma [<xref rid="bib157" ref-type="bibr">155</xref>]; (iv) reducing the production of NO by inducing the production of nitric oxide synthase 2 (NOS2) isoforms [<xref rid="bib158" ref-type="bibr">156</xref>]; (v) decreasing the release of histamine and other mediators from basophils and mast cells [<xref rid="bib159" ref-type="bibr">157</xref>]; (vi) reducing the production of immunoglobulin G (IgG) [<xref rid="bib160" ref-type="bibr">158</xref>]; (vii) increasing the synthesis of anti-inflammatory factors such as IL-10, IL-1 soluble receptor, and clusterin [<xref rid="bib161" ref-type="bibr">159</xref>]; (viii) endogenous GCs entering the bloodstream increase in quantity during inflammation and stress events [<xref rid="bib162" ref-type="bibr">160</xref>], playing a crucial regulatory role in preventing excessive activation of inflammation and other potent defense responses, which, if left uncontrolled, may lead to a state of dysregulation in the organism [<xref rid="bib163" ref-type="bibr">161</xref>].</p></sec></sec><sec id="sec4"><label>4</label><title>Association between chronic obstructive pulmonary disease (COPD) and LC</title><sec id="sec4.1"><label>4.1</label><title>Interrelated pathogenesis of COPD and LC</title><p id="p0140">Globally, COPD and LC are prominent contributors to high morbidity and mortality in chronic respiratory diseases [<xref rid="bib164" ref-type="bibr">162</xref>]. In 2016, COPD ranked as the fifth most prevalent cause of mortality in China, with projections anticipating its elevation to the third leading cause of death by 2030 [<xref rid="bib165" ref-type="bibr">163</xref>]. LC remains the primary cause of cancer-related deaths, imposing significant social and economic burdens [<xref rid="bib166" ref-type="bibr">164</xref>,<xref rid="bib167" ref-type="bibr">165</xref>]. A correlation exists between COPD and LC, sharing common risk factors such as smoking, environmental exposure, and occupational hazards, along with similar pathogenesis mechanisms, including chronic inflammation, oxidative stress, and lung aging [<xref rid="bib168" ref-type="bibr">166</xref>,<xref rid="bib169" ref-type="bibr">167</xref>]. The precise mechanisms by which COPD transitions to LC remain unclear, but evidence suggests that chronic inflammation, epigenetic modifications, genetic susceptibility, and environmental factors play a role in this transformation [<xref rid="bib170" ref-type="bibr">168</xref>]. Smokers with COPD have up to a fivefold higher risk of developing LC than those with other lung diseases [<xref rid="bib171" ref-type="bibr">169</xref>]. COPD is a significant risk factor for LC, regardless of smoking status. Lung inflammation and pulmonary matrix remodeling may serve as crucial precursors to the development of LC [<xref rid="bib172" ref-type="bibr">[170]</xref>, <xref rid="bib173" ref-type="bibr">[171]</xref>, <xref rid="bib174" ref-type="bibr">[172]</xref>]. Details are shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Pathophysiological links between smoking, genetic susceptibility, immune response, and the development of COPD and LC. The link between COPD and LC is intricately connected, with both conditions occurring in aging lungs. Moreover, oxidative stress can serve as a common trigger for both. Each cigarette contains approximately 10<sup>15</sup> free radicals, including reactive nitrogen and oxygen species (RNOS), which can cause tumor proliferation through DNA damage and lead to COPD through inflammation. Additionally, COPD and LC share several pathological factors, such as telomere shortening, genetic susceptibility, and epigenetics.</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0145">In addition to shared etiological factors, LC and COPD demonstrate concordance in genetic vulnerability beyond the scope of tobacco-induced pathologies [<xref rid="bib175" ref-type="bibr">173</xref>]. The exploration of genome-wide association studies (GWAS) focusing on lung function and LC has revealed numerous common loci, suggesting a shared genetic basis between susceptibility to COPD and LC in smokers [<xref rid="bib176" ref-type="bibr">174</xref>]. Epithelial-mesenchymal transition (EMT) is a common pathological characteristic of both COPD and LC, alongside inflammatory processes [<xref rid="bib177" ref-type="bibr">175</xref>]. Notably, the rs7326277TT genotype in VEGFR1 potentiates these pathways and tumor progression, presenting as a susceptibility locus for both diseases [<xref rid="bib178" ref-type="bibr">176</xref>].</p><p id="p0150">Compared with smokers with normal pulmonary function, individuals with mild to moderate COPD face a threefold increase in the risk of developing LC within a decade [<xref rid="bib179" ref-type="bibr">177</xref>]. This risk increases tenfold in those with severe COPD [<xref rid="bib180" ref-type="bibr">178</xref>]. The inflammatory environment associated with COPD is implicated in this elevated cancer risk [<xref rid="bib181" ref-type="bibr">179</xref>]. Chronic inflammation in COPD can lead to persistent mitosis, increasing the likelihood of endogenous DNA damage mutating into cancerous changes [<xref rid="bib182" ref-type="bibr">180</xref>]. Chronic inflammation caused by airway obstruction may play a critical role in lung carcinogenesis and could be a significant component of the field cancerization effect. In COPD, chronic inflammation within the airways, particularly in the small airways, is characterized by an accumulation of macrophages, CD4<sup>+</sup> and CD8<sup>+</sup> T cells, DCs, and neutrophils. Chronic inflammation in the lower airways is hypothesized to induce carcinogenesis, with inflammatory mediators in these microenvironments strengthening bronchioalveolar stem cells and inducing pro-tumorigenic mutations, proliferation, resistance to apoptosis, angiogenesis, invasion, metastasis, and the secretion of immunosuppressive factors [<xref rid="bib183" ref-type="bibr">181</xref>].</p></sec><sec id="sec4.2"><label>4.2</label><title>Impact of COPD on LC prognosis</title><p id="p0155">In addition to their close association with the pathogenesis, COPD influences the prognosis of LC. In a study involving 105,304 LC patients, the presence of COPD was independently associated with poorer survival. In another retrospective study involving 902 stage IA&#8211;IB NSCLC patients, those with COPD had a 5-year OS of 54.4&#160;%, significantly lower than the 69.0&#160;% in patients without COPD. The 5-year progression-free survival (PFS) in patients with COPD was 50.1&#160;% compared with 60.6&#160;% in those without COPD [<xref rid="bib184" ref-type="bibr">182</xref>]. Furthermore, the severity of COPD affects the incidence of LC. In a longitudinal follow-up study of 5402 COPD patients over 22 years, the presence of moderate to severe COPD increased the risk of developing LC by 2.8 times [<xref rid="bib185" ref-type="bibr">183</xref>].</p></sec><sec id="sec4.3"><label>4.3</label><title>Impact of COPD on LC treatment outcomes</title><p id="p0160">COPD affects the management of LC. Generally, assessing lung function preoperatively using forced expiratory volume in 1&#160;s (FEV1) and diffusing capacity for carbon monoxide (DLCO) is necessary. Recent guidelines recommend cardiopulmonary exercise testing to calculate surgical risk if predicted postoperative (PPO) FEV1 and/or PPO DLCO are less than 30&#160;% of the predicted value. This categorizes patients with severe COPD (preoperative FEV1&#160;&lt;&#160;50&#160;% predicted) as high-risk, often contraindicating surgery in many cases [<xref rid="bib186" ref-type="bibr">184</xref>].</p><p id="p0165">In a real-world study in China, clinical outcomes were compared between LC patients who did and did not receive regular COPD treatment. Results showed no significant difference in the objective response rate (ORR) and disease control rate (DCR) between the two groups. However, patients receiving regular COPD treatment had significantly longer PFS and OS, suggesting that standard management of COPD in NSCLC patients can extend OS and PFS [<xref rid="bib187" ref-type="bibr">185</xref>].</p><p id="p0170">Regarding prevention, inhaled GCs (ICSs) may be an effective measure. A 2021 meta-analysis reviewed studies published between 1974 and 2020 on the association between ICS use and LC risk, ultimately including ten studies with 234,920 patients. The analysis showed that ICS use could reduce the risk of LC in COPD patients. It could also decrease the risk of LC in asthma patients as well as in patients with both COPD and asthma [<xref rid="bib188" ref-type="bibr">186</xref>].</p></sec><sec id="sec4.4"><label>4.4</label><title>Screening and early diagnosis of LC in COPD patients</title><p id="p0175">Despite the intricate connections between COPD and LC in terms of pathogenesis, prognosis, prevention, and treatment, the diagnosis and management of COPD among LC patients in China face significant challenges [<xref rid="bib189" ref-type="bibr">187</xref>]. A retrospective analysis of 703 LC patients who underwent comprehensive pulmonary function testing revealed that approximately 92.5&#160;% of pre-surgical patients met the diagnostic criteria for COPD, with a similar percentage of 92.7&#160;% among those undergoing surgery. In contrast, only three cases (0.43&#160;%) were diagnosed with COPD and received standardized treatment prior to hospitalization, and merely five cases (0.7&#160;%) were diagnosed upon discharge. This finding indicates a lack of sufficient attention to COPD in LC patients within clinical practice.</p><p id="p0180">Globally, tools have been developed to screen for high-risk LC patients among those with COPD. Regression analysis identified independent correlations with LC diagnosis, including age &gt;60 years, BMI &lt;25&#160;kg/m<sup>2</sup>, smoking pack-years &gt;60, and DLCO &lt;60&#160;%. The COPD-LUCSS-DLCO tool can assess LC risk in COPD patients, categorizing them into low risk (0&#8211;3 points) and high risk. High-risk patients have a 2.4 times higher risk of dying from LC than low-risk patients [<xref rid="bib190" ref-type="bibr">188</xref>].</p><p id="p0185">Therefore, recognizing the LC risk within the COPD patient cohort underscores the imperative for vigilant screening and preventive measures. Beyond the shared etiological contributors, the management of COPD, including the strategic use of high-dose inhaled corticosteroids, confers a pivotal role in mitigating LC risk. This advocates for an integrated approach to patient care that addresses both the pulmonary and oncological dimensions of COPD and LC.</p></sec><sec id="sec4.5"><label>4.5</label><title>Association between ICSs and LC risk in patients with COPD</title><p id="p0190">Research has established a link of systemic inflammation to the frequent exacerbations and higher mortality rates in patients with COPD [<xref rid="bib191" ref-type="bibr">189</xref>]. ICSs are non-specific anti-inflammatory medications widely used in the clinical management of COPD to alleviate severe symptoms, reduce acute exacerbations, improve pulmonary function, and enhance patient quality of life. Studies suggest that chronic inflammation associated with COPD may lead to changes in the bronchial epithelium, potentially initiating LC [<xref rid="bib192" ref-type="bibr">190</xref>]. Consequently, the association between ICS use and LC risk has been observed, indicating that ICS may serve a chemopreventive role against LC. However, current clinical guidelines have yet to provide recommendations on this matter, and some studies have found no association between ICS use and reduced LC risk [<xref rid="bib193" ref-type="bibr">191</xref>].</p><p id="p0195">Preliminary explorations into the chemopreventive role of ICSs against LC have been conducted in animal models and clinical trials, though the mechanisms remain unclear [<xref rid="bib194" ref-type="bibr">192</xref>]. Mahmood et al. found that the precursor to malignant tumors, type III EMT, is active in the airways of COPD patients, but this change can be mitigated through ICS treatment [<xref rid="bib195" ref-type="bibr">193</xref>]. Thus, ICSs may inhibit the chronic inflammatory process in the airways of COPD patients by suppressing the activation of airway epithelial cells and EMT, thereby preventing the onset of LC. However, these findings require further confirmatory studies for validation [<xref rid="bib196" ref-type="bibr">194</xref>].</p></sec></sec><sec id="sec5"><label>5</label><title>Impact of GC use on the efficacy of ICIs in advanced NSCLC</title><p id="p0200">GCs, a class of hormones with anti-inflammatory, anti-allergic, and anti-shock properties, are utilized in the anti-tumor treatment of certain cancers and are widely used to prevent and alleviate the adverse reactions of chemotherapy drugs [<xref rid="bib197" ref-type="bibr">195</xref>]. High-dose GC use affects the effectiveness of immunotherapy [<xref rid="bib198" ref-type="bibr">196</xref>]. This condition is attributed to the mechanism that high-dose GCs suppress the activation, proliferation, and function of immune cells (such as T cells, NK cells, and DCs), thereby reducing the capacity of the immune system to attack tumor cells [<xref rid="bib199" ref-type="bibr">197</xref>]. Additionally, high-dose GCs increase the levels of PD-L1 expression on tumor cells (a molecule that can bind to PD-1 and inhibit T cell responses), thereby increasing tumor cell resistance to ICIs (such as PD-1/PD-L1 inhibitors) [<xref rid="bib200" ref-type="bibr">198</xref>,<xref rid="bib201" ref-type="bibr">199</xref>]. Several clinical trials have confirmed the detrimental impact of high-dose GC use on the efficacy of immunotherapy. An analysis of data from 640 LC patients who received immunotherapy between 2011 and 2017 found that the median OS of 90 patients using &#8805;10&#160;mg of prednisone (a commonly used oral or intravenous synthetic potent steroid) was significantly shorter than that of those using &lt;10&#160;mg of prednisone or not using prednisone at all [<xref rid="bib202" ref-type="bibr">200</xref>]. Another retrospective analysis of 196 NSCLC patients treated with ICIs found that patients using high-dose GCs (&gt;10&#160;mg of prednisone equivalent) to alleviate cancer-related symptoms experienced significantly lower OS and PFS than those who did not use GCs or used low-dose GCs (&#8804;10&#160;mg of prednisone equivalent) [<xref rid="bib203" ref-type="bibr">201</xref>]. These findings indicate that high-dose GC use may reduce the effectiveness of immunotherapy in LC patients.</p><p id="p0205">Patients undergoing immunotherapy may experience side effects, and GCs, a type of steroid, can be used to treat these side effects [<xref rid="bib204" ref-type="bibr">202</xref>]. GCs are commonly used to modulate immune responses in asthma, Crohn's disease, and even COVID-19 [<xref rid="bib205" ref-type="bibr">203</xref>]. In a recent study, researchers from the Cold Spring Harbor Laboratory (CSHL) in the United States may have come closer to elucidating how GCs could indirectly contribute to the failure of some immunotherapies [<xref rid="bib206" ref-type="bibr">204</xref>]. Their study suggests that GCs may stimulate the production of a protein called cystatin C (CyC), and higher levels of CyC are associated with poorer outcomes in this type of therapy.</p><p id="p0210">The immunosuppressive nature of GCs, particularly pivotal for managing ICI-induced irAEs, necessitates their cautious application in the treatment of advanced NSCLC [<xref rid="bib207" ref-type="bibr">205</xref>]. Patients with advanced NSCLC may require GCs to control related clinical symptoms such as dyspnea, pulmonary infections, and palliative care [<xref rid="bib208" ref-type="bibr">206</xref>]. A retrospective analysis by Fuc&#224; et al., encompassing 151 NSCLC patients treated with ICI, found that GCs increased the risk of PFS by 80&#160;% [<xref rid="bib209" ref-type="bibr">207</xref>]. Petrelli et al.demonstrated that patients taking steroids had increased risks of OS and PFS compared with those not taking steroids [<xref rid="bib210" ref-type="bibr">208</xref>]. Moreover, they revealed that steroids used for brain metastases and supportive care were adverse factors for OS but not when used for treating irAEs [<xref rid="bib211" ref-type="bibr">209</xref>]. This finding may be attributed to the subgroup of patients receiving palliative care with corticosteroids inherently having a poorer overall prognosis. The adverse effects of corticosteroids are significant only when treating tumor-related palliative indications and are not associated with poor prognosis when used for non-tumor-related conditions, such as autoimmune diseases, exacerbations of COPD, and preventing allergic reactions. In the KEYNOTE-407 study, adding pembrolizumab to a platinum-based chemotherapy regimen improved OS in squamous NSCLC patients, regardless of whether paclitaxel requiring steroid premedication for allergy prevention or albumin-bound paclitaxel not requiring premedication was used. In the treatment of NSCLC patients with ICI, the use of steroid hormones to control symptoms caused by the tumor itself requires caution [<xref rid="bib212" ref-type="bibr">210</xref>].</p></sec><sec id="sec6"><label>6</label><title>Research on reshaping the TME</title><p id="p0215">Reshaping the TIME is a critical strategy for enhancing the efficacy of immunotherapy. The transformation of the TME through existing strategies, as well as the discovery of new ones, is essential for developing immunotherapies that can adapt to the complexities of the TME [<xref rid="bib213" ref-type="bibr">211</xref>]. Enhancing the efficacy of cancer immunotherapy is a central focus of current and future research endeavors, with the anticipation of novel pharmacological discoveries. GCs are pivotal hormones in regulating immune responses, playing a key role in the development, differentiation, activation, and inflammatory responses of immune cells [<xref rid="bib214" ref-type="bibr">212</xref>]. However, their misapplication poses a risk of fostering immunosuppression and tumor development, rendering the study of the influence of GCs on the immune microenvironment highly relevant.</p><p id="p0220">On the one hand, GCs can influence immune responses by regulating the functions of DCs and T cells [<xref rid="bib215" ref-type="bibr">213</xref>]. Studies have shown that GCs enhance the maturation and antigen-presenting ability of DCs while inhibiting the activation and proliferation of T cells [<xref rid="bib216" ref-type="bibr">[214]</xref>, <xref rid="bib217" ref-type="bibr">[215]</xref>, <xref rid="bib218" ref-type="bibr">[216]</xref>]. This regulatory action helps maintain immune homeostasis but may also lead to immunosuppression and tumor progression. Therefore, a comprehensive understanding of the regulatory mechanisms of GCs on immune cells can offer new strategies for cancer immunotherapy. On the other hand, GCs regulate tumor progression by influencing the TME [<xref rid="bib219" ref-type="bibr">217</xref>]. Elevated levels of GCs in the TME may promote the proliferation, invasion, and metastasis of tumor cells. Research indicates that GCs can promote the growth and survival of tumor cells by activating signaling pathways such as PI3K/Akt and MAPK/ERK. Therefore, reducing GC levels or inhibiting their associated signaling pathways may help suppress tumor progression and enhance the effects of immunotherapy [<xref rid="bib220" ref-type="bibr">218</xref>].</p><p id="p0225">The TNF superfamily comprises molecules pivotal to the orchestration and efficacy of both innate and adaptive immune responses, making many members of this family targets for drug development in tumor immunotherapy and anti-inflammatory medication [<xref rid="bib221" ref-type="bibr">219</xref>]. The GC-induced TNF receptor family-related protein (GITR) is an immune checkpoint molecule involved in the regulation of T cell responses [<xref rid="bib222" ref-type="bibr">220</xref>]. The phenomenon that the single structural domain of GITR mediates its binding with ligands suggests that this unique mode of action may represent an ancient binding pattern in the evolution of the TNF/TNFR superfamily [<xref rid="bib223" ref-type="bibr">221</xref>,<xref rid="bib224" ref-type="bibr">222</xref>]. In contrast, other TNFR superfamily members have evolved to bind with ligands through two distinct structural domains for specificity and high affinity [<xref rid="bib225" ref-type="bibr">223</xref>]. Activating monoclonal antibodies targeting GITR have shown good drug tolerance and significant tumor-suppressive activity in clinical studies, providing a crucial theoretical basis for understanding T cell immune regulation mechanisms and drug development based on immune checkpoint molecules [<xref rid="bib226" ref-type="bibr">224</xref>,<xref rid="bib227" ref-type="bibr">225</xref>].</p><p id="p0230">Collectively, the study of the role of GCs in modulating the immune microenvironment holds promise for innovating cancer immunotherapy strategies and methodologies. Future research should delve deeper into the regulatory mechanisms of GCs on immune and tumor cells and investigate how intervening in the actions of GCs can enhance the effectiveness of immunotherapy. Concurrently, considering individual differences and drug side effects, there is a need for cautious use of related drugs in clinical practice, along with strengthened monitoring of drug efficacy and management of adverse reactions.</p></sec><sec id="sec7"><title>Funding</title><p id="p0235">This study is supported by <funding-source id="gs1">Jiangsu Province Traditional Chinese Medicine Science and Technology Development</funding-source> Project: Clinical and mechanistic study on dry salt aerosol therapy combined with ginseng herb capsule in the prevention and treatment of the progression of chronic obstructive pulmonary disease (COPD) and asthma (Fund number: <award-id award-type="grant" rid="gs1">ZT202209</award-id>).</p></sec><sec id="sec9"><title>CRediT authorship contribution statement</title><p id="p0245"><bold>Wenhui Xu:</bold> Writing &#8211; original draft. <bold>Jinghong Ye:</bold> Writing &#8211; original draft. <bold>Zhendong Cao:</bold> Conceptualization. <bold>Yupei Zhao:</bold> Validation. <bold>Yimin Zhu:</bold> Writing &#8211; review &amp; editing. <bold>Lei Li:</bold> Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0250">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Lei Li reports financial support was provided by <funding-source id="gs2">Jiangsu Province Traditional Chinese Medicine Science and Technology Development</funding-source> Project. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>Development and validation of a dna methylation-related classifier of circulating tumour cells to predict prognosis and to provide a therapeutic strategy in lung adenocarcinoma</article-title><source>Int. J. Biol. Sci.</source><volume>18</volume><issue>13</issue><year>2022</year><fpage>4984</fpage><lpage>5000</lpage><pub-id pub-id-type="doi">10.7150/ijbs.75284</pub-id><pub-id pub-id-type="pmid">35982906</pub-id><pub-id pub-id-type="pmcid">PMC9379404</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>G.Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T.W.</given-names></name></person-group><article-title>Lung adenocarcinoma pathology stages related gene identification</article-title><source>Math. Biosci. Eng. : MBE</source><volume>17</volume><issue>1</issue><year>2019</year><fpage>737</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.3934/mbe.2020038</pub-id><pub-id pub-id-type="pmid">31731374</pub-id></element-citation></ref><ref id="bib3"><label>3</label><mixed-citation publication-type="other" id="sref3">X. Xiao, Q. Guo, C. Cui, et al., Multiplexed imaging mass cytometry reveals distinct tumor-immune microenvironments linked to immunotherapy responses in melanoma., Communications medicine 22022) 131, <pub-id pub-id-type="doi">10.1038/s43856-022-00197-2</pub-id>.<pub-id pub-id-type="pmcid">PMC9587266</pub-id><pub-id pub-id-type="pmid">36281356</pub-id></mixed-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma</article-title><source>J. Transl. Med.</source><volume>21</volume><issue>1</issue><year>2023</year><fpage>489</fpage><pub-id pub-id-type="doi">10.1186/s12967-023-04336-8</pub-id><pub-id pub-id-type="pmid">37474942</pub-id><pub-id pub-id-type="pmcid">PMC10360235</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Campomenosi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mortara</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bassani</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The potential role of the t2 ribonucleases in tme-based cancer therapy</article-title><source>Biomedicines</source><volume>11</volume><issue>8</issue><year>2023</year><pub-id pub-id-type="doi">10.3390/biomedicines11082160</pub-id><pub-id pub-id-type="pmcid">PMC10452627</pub-id><pub-id pub-id-type="pmid">37626657</pub-id></element-citation></ref><ref id="bib6"><label>6</label><mixed-citation publication-type="other" id="sref6">M. Rafat, M. Kohsarian, M. Bahiraei, A.R. Nikpoor, A comprehensive study on signal transduction and therapeutic role of mir-877 in human cancers., Adv. Biomed. Res. 122023) 118, <pub-id pub-id-type="doi">10.4103/abr.abr_412_21</pub-id>.<pub-id pub-id-type="pmcid">PMC10331537</pub-id><pub-id pub-id-type="pmid">37434921</pub-id></mixed-citation></ref><ref id="bib7"><label>7</label><mixed-citation publication-type="other" id="sref7">B.T. Fuller, E.M. Buczynksi, P.E. Beshay, J.W. Song, Molecular sensors for detection of tumor-stroma crosstalk., Adv. Cancer Res. 1542022) 47-91, <pub-id pub-id-type="doi">10.1016/bs.acr.2022.01.001</pub-id>.<pub-id pub-id-type="pmid">35459472</pub-id></mixed-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Pur&#233;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>A.</given-names></name></person-group><article-title>Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors?</article-title><source>Cancer Immunol. Res.</source><volume>4</volume><issue>4</issue><year>2016</year><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0011</pub-id><pub-id pub-id-type="pmid">27036971</pub-id><pub-id pub-id-type="pmcid">PMC5452418</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Najaflou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shahgolzari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khosroushahi</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Fiering</surname><given-names>S.</given-names></name></person-group><article-title>Tumor-derived extracellular vesicles in cancer immunoediting and their potential as oncoimmunotherapeutics</article-title><source>Cancers</source><volume>15</volume><issue>1</issue><year>2022</year><pub-id pub-id-type="doi">10.3390/cancers15010082</pub-id><pub-id pub-id-type="pmcid">PMC9817790</pub-id><pub-id pub-id-type="pmid">36612080</pub-id></element-citation></ref><ref id="bib10"><label>10</label><mixed-citation publication-type="other" id="sref10">A.R. Lim, W.K. Rathmell, J.C. Rathmell, The tumor microenvironment as a metabolic barrier to effector t cells and immunotherapy., Elife 92020), <pub-id pub-id-type="doi">10.7554/eLife.55185</pub-id>.<pub-id pub-id-type="pmcid">PMC7200151</pub-id><pub-id pub-id-type="pmid">32367803</pub-id></mixed-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Sugiyama</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hinohara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>H.</given-names></name></person-group><article-title>Significance of regulatory t cells in cancer immunology and immunotherapy</article-title><source>Exp. Dermatol.</source><volume>32</volume><issue>3</issue><year>2023</year><fpage>256</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1111/exd.14721</pub-id><pub-id pub-id-type="pmid">36458459</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The impact of host immune cells on the development of neurofibromatosis type 1: the abnormal immune system provides an immune microenvironment for tumorigenesis</article-title><source>Neuro-oncology advances</source><volume>1</volume><issue>1</issue><year>2019</year><fpage>vdz37</fpage><pub-id pub-id-type="doi">10.1093/noajnl/vdz037</pub-id><pub-id pub-id-type="pmcid">PMC7212924</pub-id><pub-id pub-id-type="pmid">32642666</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Differentiation and immunological function of mdsc-derived dendritic cells</article-title><source>Glob. Med. Genet.</source><volume>9</volume><issue>4</issue><year>2022</year><fpage>290</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1055/s-0042-1756659</pub-id><pub-id pub-id-type="pmid">36567953</pub-id><pub-id pub-id-type="pmcid">PMC9771685</pub-id></element-citation></ref><ref id="bib14"><label>14</label><mixed-citation publication-type="other" id="sref14">A. Preet Kaur, A. Alice, M.R. Crittenden, M.J. Gough, The role of dendritic cells in radiation-induced immune responses., Int. Rev. Cell Mol. Biol. 3782023) 61-104, <pub-id pub-id-type="doi">10.1016/bs.ircmb.2023.02.002</pub-id>.<pub-id pub-id-type="pmid">37438021</pub-id></mixed-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Immunogenic panoptosis-initiated cancer sono-immune reediting nanotherapy by iteratively boosting cancer immunity cycle</article-title><source>Advanced materials (Deerfield Beach, Fla.)</source><volume>36</volume><issue>2</issue><year>2024</year><object-id pub-id-type="publisher-id">e2305361</object-id><pub-id pub-id-type="doi">10.1002/adma.202305361</pub-id><pub-id pub-id-type="pmid">37699593</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Shihab</surname><given-names>I.</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Elemam</surname><given-names>N.M.</given-names></name><etal/></person-group><article-title>Understanding the role of innate immune cells and identifying genes in breast cancer microenvironment</article-title><source>Cancers</source><volume>12</volume><issue>8</issue><year>2020</year><pub-id pub-id-type="doi">10.3390/cancers12082226</pub-id><pub-id pub-id-type="pmcid">PMC7464944</pub-id><pub-id pub-id-type="pmid">32784928</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Akintola</surname><given-names>O.O.</given-names></name><name name-style="western"><surname>Reardon</surname><given-names>D.A.</given-names></name></person-group><article-title>The current landscape of immune checkpoint blockade in glioblastoma</article-title><source>Neurosurg. Clin.</source><volume>32</volume><issue>2</issue><year>2021</year><fpage>235</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.nec.2020.12.003</pub-id><pub-id pub-id-type="pmid">33781505</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Regulatory t cells and potential inmmunotherapeutic targets in lung cancer</article-title><source>Cancer Metastasis Rev.</source><volume>34</volume><issue>2</issue><year>2015</year><fpage>277</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1007/s10555-015-9566-0</pub-id><pub-id pub-id-type="pmid">25962964</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Bracey</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Maltzman</surname><given-names>J.S.</given-names></name></person-group><article-title>Cd8 t(regs) sqa-1shing transplant rejection</article-title><source>Sci. Immunol.</source><volume>8</volume><issue>90</issue><year>2023</year><object-id pub-id-type="publisher-id">eadn644</object-id><pub-id pub-id-type="doi">10.1126/sciimmunol.adn0644</pub-id><pub-id pub-id-type="pmid">38039378</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Navasardyan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bonavida</surname><given-names>B.</given-names></name></person-group><article-title>Regulation of t cells in cancer by nitric oxide</article-title><source>Cells</source><volume>10</volume><issue>10</issue><year>2021</year><pub-id pub-id-type="doi">10.3390/cells10102655</pub-id><pub-id pub-id-type="pmcid">PMC8534057</pub-id><pub-id pub-id-type="pmid">34685635</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Tespa1 deficiency reduces the antitumour immune response by decreasing cd8(+)t cell activity in a mouse lewis lung cancer model</article-title><source>Int. Immunopharm.</source><volume>124</volume><issue>Pt A</issue><year>2023</year><object-id pub-id-type="publisher-id">110865</object-id><pub-id pub-id-type="doi">10.1016/j.intimp.2023.110865</pub-id><pub-id pub-id-type="pmid">37660596</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Ke</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name></person-group><article-title>Targeting cytokines secreted by cd4(+) cd25(high) cd127(low) regulatory t cells inhibits ovarian cancer progression</article-title><source>Scand. J. Immunol.</source><volume>89</volume><issue>2</issue><year>2019</year><object-id pub-id-type="publisher-id">e12736</object-id><pub-id pub-id-type="doi">10.1111/sji.12736</pub-id><pub-id pub-id-type="pmid">30485902</pub-id></element-citation></ref><ref id="bib23"><label>23</label><mixed-citation publication-type="other" id="sref23">K. Bergerhoff, M. Pedersen, Isolation and analysis of tumor-infiltrating treg., Methods in molecular biology (Clifton, N.J.) 25592023) 51-63, <pub-id pub-id-type="doi">10.1007/978-1-0716-2647-4_5</pub-id>.<pub-id pub-id-type="pmid">36180626</pub-id></mixed-citation></ref><ref id="bib24"><label>24</label><mixed-citation publication-type="other" id="sref24">Y. Wang, E.C. Song, M.B. Resnick, Elastin in the tumor microenvironment., Adv. Exp. Med. Biol. 12722020) 1-16, <pub-id pub-id-type="doi">10.1007/978-3-030-48457-6_1</pub-id>.<pub-id pub-id-type="pmid">32845499</pub-id></mixed-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Saint</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Obberghen-Schilling</surname><given-names>E.</given-names></name></person-group><article-title>The role of the tumor matrix environment in progression of head and neck cancer</article-title><source>Curr. Opin. Oncol.</source><volume>33</volume><issue>3</issue><year>2021</year><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1097/CCO.0000000000000730</pub-id><pub-id pub-id-type="pmid">33720067</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Nuclear factor 90 promotes angiogenesis by regulating hif-1&#945;/vegf-a expression through the pi3k/akt signaling pathway in human cervical cancer</article-title><source>Cell Death Dis.</source><volume>9</volume><issue>3</issue><year>2018</year><fpage>276</fpage><pub-id pub-id-type="doi">10.1038/s41419-018-0334-2</pub-id><pub-id pub-id-type="pmid">29449553</pub-id><pub-id pub-id-type="pmcid">PMC5833414</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bopan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name></person-group><article-title>High basp1 expression is associated with poor prognosis and promotes tumor progression in human lung adenocarcinoma</article-title><source>Cancer Invest.</source><volume>39</volume><issue>5</issue><year>2021</year><fpage>409</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1080/07357907.2021.1910290</pub-id><pub-id pub-id-type="pmid">33813994</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zingone</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma</article-title><source>Genome Med.</source><volume>14</volume><issue>1</issue><year>2022</year><fpage>126</fpage><pub-id pub-id-type="doi">10.1186/s13073-022-01127-6</pub-id><pub-id pub-id-type="pmid">36404344</pub-id><pub-id pub-id-type="pmcid">PMC9677915</pub-id></element-citation></ref><ref id="bib29"><label>29</label><mixed-citation publication-type="other" id="sref29">K.J. Hogan, M.R. Perez, A.G. Mikos, Extracellular matrix component-derived nanoparticles for drug delivery and tissue engineering., J. Contr. Release : official journal of the Controlled Release Society 3602023) 888-912, <pub-id pub-id-type="doi">10.1016/j.jconrel.2023.07.034</pub-id>.<pub-id pub-id-type="pmid">37482344</pub-id></mixed-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Noriega-Guerra</surname><given-names>H.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>V.M.</given-names></name></person-group><article-title>Extracellular matrix influencing hgf/c-met signaling pathway: impact on cancer progression</article-title><source>Int. J. Mol. Sci.</source><volume>19</volume><issue>11</issue><year>2018</year><pub-id pub-id-type="doi">10.3390/ijms19113300</pub-id><pub-id pub-id-type="pmcid">PMC6274944</pub-id><pub-id pub-id-type="pmid">30352967</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Extracellular matrix and its therapeutic potential for cancer treatment</article-title><source>Signal Transduct. Targeted Ther.</source><volume>6</volume><issue>1</issue><year>2021</year><fpage>153</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00544-0</pub-id><pub-id pub-id-type="pmcid">PMC8062524</pub-id><pub-id pub-id-type="pmid">33888679</pub-id></element-citation></ref><ref id="bib32"><label>32</label><mixed-citation publication-type="other" id="sref32">S. Wang, Z. Chen, F. Gao, et al., Remodeling extracellular matrix based on functional covalent organic framework to enhance tumor photodynamic therapy., Biomaterials 2342020) 119772, <pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.119772</pub-id>.<pub-id pub-id-type="pmid">31945618</pub-id></mixed-citation></ref><ref id="bib33"><label>33</label><mixed-citation publication-type="other" id="sref33">S. Dutta, S. Sen, Preparation and characterization of collagen-hyaluronic acid (col-ha) matrices: in vitro mimics of the tumor microenvironment., Methods in molecular biology (Clifton, N.J.) 27472024) 131-139, <pub-id pub-id-type="doi">10.1007/978-1-0716-3589-6_11</pub-id>.<pub-id pub-id-type="pmid">38038937</pub-id></mixed-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>H.</given-names></name></person-group><article-title>Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy</article-title><source>J. Hematol. Oncol.</source><volume>15</volume><issue>1</issue><year>2022</year><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s13045-022-01252-0</pub-id><pub-id pub-id-type="pmid">35331296</pub-id><pub-id pub-id-type="pmcid">PMC8943941</pub-id></element-citation></ref><ref id="bib35"><label>35</label><mixed-citation publication-type="other" id="sref35">M.A. Erdogan, D. Ugo, F. Ines, The role of ion channels in the relationship between the immune system and cancer., Curr. Top. Membr. 922023) 151-198, <pub-id pub-id-type="doi">10.1016/bs.ctm.2023.09.001</pub-id>.<pub-id pub-id-type="pmid">38007267</pub-id></mixed-citation></ref><ref id="bib37"><label>36</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>A.</given-names></name><name name-style="western"><surname>Greenshields-Watson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Immune remodeling of the extracellular matrix drives loss of cancer stem cells and tumor rejection</article-title><source>Cancer Immunol. Res.</source><volume>8</volume><issue>12</issue><year>2020</year><fpage>1520</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-20-0070</pub-id><pub-id pub-id-type="pmid">33023965</pub-id><pub-id pub-id-type="pmcid">PMC7611107</pub-id></element-citation></ref><ref id="bib38"><label>37</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Ingram</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Cell membrane-anchored and tumor-targeted il-12 t-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models</article-title><source>J. Immunother. Cancer</source><volume>12</volume><issue>1</issue><year>2024</year><pub-id pub-id-type="doi">10.1136/jitc-2023-006991</pub-id><pub-id pub-id-type="pmcid">PMC10806671</pub-id><pub-id pub-id-type="pmid">38199607</pub-id></element-citation></ref><ref id="bib39"><label>38</label><mixed-citation publication-type="other" id="sref39">K. Xu, C. Zhang, T. Du, et al., Progress of exosomes in the diagnosis and treatment of lung cancer., Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie 1342021) 111111, <pub-id pub-id-type="doi">10.1016/j.biopha.2020.111111</pub-id>.<pub-id pub-id-type="pmid">33352449</pub-id></mixed-citation></ref><ref id="bib40"><label>39</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Maurya</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sandur</surname><given-names>S.K.</given-names></name></person-group><article-title>Hypoxia induces dichotomous and reversible attenuation of t cell responses through reactive oxygen species-dependent phenotype redistribution and delay in lymphoblast proliferation</article-title><source>Free Radic. Res.</source><volume>57</volume><issue>1</issue><year>2023</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1080/10715762.2023.2178918</pub-id><pub-id pub-id-type="pmid">36947008</pub-id></element-citation></ref><ref id="bib41"><label>40</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.S.</given-names></name><etal/></person-group><article-title>Homeobox protein hhex negatively regulates treg cells by inhibiting foxp3 expression and function</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>116</volume><issue>51</issue><year>2019</year><fpage>25790</fpage><lpage>25799</lpage><pub-id pub-id-type="doi">10.1073/pnas.1907224116</pub-id><pub-id pub-id-type="pmid">31792183</pub-id><pub-id pub-id-type="pmcid">PMC6926046</pub-id></element-citation></ref><ref id="bib42"><label>41</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Kasai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Funaki</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Trans-homophilic interaction of cadm1 promotes organ infiltration of t-cell lymphoma by adhesion to vascular endothelium</article-title><source>Cancer Sci.</source><volume>113</volume><issue>5</issue><year>2022</year><fpage>1669</fpage><lpage>1678</lpage><pub-id pub-id-type="doi">10.1111/cas.15307</pub-id><pub-id pub-id-type="pmid">35213073</pub-id><pub-id pub-id-type="pmcid">PMC9128163</pub-id></element-citation></ref><ref id="bib43"><label>42</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Decoding macrophage subtypes to engineer modulating hydrogels for the alleviation of intervertebral disk degeneration</article-title><source>Adv. Sci.</source><volume>11</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">e2304480</object-id><pub-id pub-id-type="doi">10.1002/advs.202304480</pub-id><pub-id pub-id-type="pmcid">PMC10767410</pub-id><pub-id pub-id-type="pmid">37939288</pub-id></element-citation></ref><ref id="bib44"><label>43</label><mixed-citation publication-type="other" id="sref44">S. You, Y. Zhu, H. Li, et al., Recombinant humanized collagen remodels endometrial immune microenvironment of chronic endometritis through macrophage immunomodulation., Regen. Biomater. 102023) rbad33, <pub-id pub-id-type="doi">10.1093/rb/rbad033</pub-id>.<pub-id pub-id-type="pmcid">PMC10147517</pub-id><pub-id pub-id-type="pmid">37122820</pub-id></mixed-citation></ref><ref id="bib45"><label>44</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The role of microenvironment in tumor angiogenesis</article-title><source>J. Exp. Clin. Cancer Res. : CR</source><volume>39</volume><issue>1</issue><year>2020</year><fpage>204</fpage><pub-id pub-id-type="doi">10.1186/s13046-020-01709-5</pub-id><pub-id pub-id-type="pmid">32993787</pub-id><pub-id pub-id-type="pmcid">PMC7526376</pub-id></element-citation></ref><ref id="bib46"><label>45</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Hinshaw</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Shevde</surname><given-names>L.A.</given-names></name></person-group><article-title>The tumor microenvironment innately modulates cancer progression</article-title><source>Cancer Res.</source><volume>79</volume><issue>18</issue><year>2019</year><fpage>4557</fpage><lpage>4566</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-3962</pub-id><pub-id pub-id-type="pmid">31350295</pub-id><pub-id pub-id-type="pmcid">PMC6744958</pub-id></element-citation></ref><ref id="bib47"><label>46</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>N.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>R.</given-names></name></person-group><article-title>Nanoparticle-based therapeutics to overcome obstacles in the tumor microenvironment of hepatocellular carcinoma</article-title><source>Nanomaterials</source><volume>12</volume><issue>16</issue><year>2022</year><pub-id pub-id-type="doi">10.3390/nano12162832</pub-id><pub-id pub-id-type="pmcid">PMC9414814</pub-id><pub-id pub-id-type="pmid">36014696</pub-id></element-citation></ref><ref id="bib48"><label>47</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Filippelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ciccone</surname><given-names>V.</given-names></name><name name-style="western"><surname>Donnini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ziche</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morbidelli</surname><given-names>L.</given-names></name></person-group><article-title>Molecular mechanisms of resistance to anti-angiogenic drugs</article-title><source>Crit. Rev. Oncog.</source><volume>26</volume><issue>2</issue><year>2021</year><fpage>39</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1615/CritRevOncog.2020035422</pub-id><pub-id pub-id-type="pmid">34347972</pub-id></element-citation></ref><ref id="bib49"><label>48</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Cantelmo</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Pircher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kalucka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carmeliet</surname><given-names>P.</given-names></name></person-group><article-title>Vessel pruning or healing: endothelial metabolism as a novel target?</article-title><source>Expert Opin. Ther. Targets</source><volume>21</volume><issue>3</issue><year>2017</year><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1080/14728222.2017.1282465</pub-id><pub-id pub-id-type="pmid">28081641</pub-id><pub-id pub-id-type="pmcid">PMC5526136</pub-id></element-citation></ref><ref id="bib50"><label>49</label><mixed-citation publication-type="other" id="sref50">Y. Yang, Y. Zhu, S. Sun, et al., Ros regulation in gliomas: implications for treatment strategies., Front. Immunol. 142023) 1259797, <pub-id pub-id-type="doi">10.3389/fimmu.2023.1259797</pub-id>.<pub-id pub-id-type="pmcid">PMC10733468</pub-id><pub-id pub-id-type="pmid">38130720</pub-id></mixed-citation></ref><ref id="bib51"><label>50</label><mixed-citation publication-type="other" id="sref51">C. Lugassy, H.K. Kleinman, N. Cassoux, R. Barnhill, Hematogenous metastasis and tumor dormancy as concepts or dogma? The continuum of vessel co-option and angiotropic extravascular migratory metastasis as an alternative., Front. Oncol. 122022) 996411, <pub-id pub-id-type="doi">10.3389/fonc.2022.996411</pub-id>.<pub-id pub-id-type="pmcid">PMC9594150</pub-id><pub-id pub-id-type="pmid">36303828</pub-id></mixed-citation></ref><ref id="bib52"><label>51</label><mixed-citation publication-type="other" id="sref52">L. Zhu, X. Zhang, X. Chen, et al., Anti-tnfr2 enhanced the antitumor activity of a new hmgn1/3m-052 stimulated dendritic cell vaccine in a mouse model of colon cancer., Biochem. Biophys. Res. Commun. 6532023) 106-114, <pub-id pub-id-type="doi">10.1016/j.bbrc.2023.02.039</pub-id>.<pub-id pub-id-type="pmid">36868074</pub-id></mixed-citation></ref><ref id="bib53"><label>52</label><mixed-citation publication-type="other" id="sref53">F.M. Yusoff, A. Nakashima, K. Kawano, et al., Implantation of hypoxia-induced mesenchymal stem cell advances therapeutic angiogenesis., Stem Cell. Int. 20222022) 6795274, <pub-id pub-id-type="doi">10.1155/2022/6795274</pub-id>.<pub-id pub-id-type="pmcid">PMC8958070</pub-id><pub-id pub-id-type="pmid">35355589</pub-id></mixed-citation></ref><ref id="bib54"><label>53</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name></person-group><article-title>Analysis of single-cell rna-sequencing data identifies a hypoxic tumor subpopulation associated with poor prognosis in triple-negative breast cancer</article-title><source>Math. Biosci. Eng. : MBE</source><volume>19</volume><issue>6</issue><year>2022</year><fpage>5793</fpage><lpage>5812</lpage><pub-id pub-id-type="doi">10.3934/mbe.2022271</pub-id><pub-id pub-id-type="pmid">35603379</pub-id></element-citation></ref><ref id="bib55"><label>54</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name></person-group><article-title>Extracellular vesicle-orchestrated crosstalk between cancer-associated fibroblasts and tumors</article-title><source>Transl. Oncol.</source><volume>14</volume><issue>12</issue><year>2021</year><object-id pub-id-type="publisher-id">101231</object-id><pub-id pub-id-type="doi">10.1016/j.tranon.2021.101231</pub-id><pub-id pub-id-type="pmcid">PMC8493591</pub-id><pub-id pub-id-type="pmid">34601397</pub-id></element-citation></ref><ref id="bib56"><label>55</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kameni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Longaker</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>J.A.</given-names></name></person-group><article-title>Medical biology of cancer-associated fibroblasts in pancreatic cancer</article-title><source>Biology</source><volume>12</volume><issue>8</issue><year>2023</year><pub-id pub-id-type="doi">10.3390/biology12081044</pub-id><pub-id pub-id-type="pmcid">PMC10451924</pub-id><pub-id pub-id-type="pmid">37626931</pub-id></element-citation></ref><ref id="bib57"><label>56</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rucki</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>Cancer-associated fibroblasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic dna methylation</article-title><source>Cancer Res.</source><volume>76</volume><issue>18</issue><year>2016</year><fpage>5395</fpage><lpage>5404</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-3264</pub-id><pub-id pub-id-type="pmid">27496707</pub-id><pub-id pub-id-type="pmcid">PMC5026619</pub-id></element-citation></ref><ref id="bib58"><label>57</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>G.</given-names></name></person-group><article-title>Targeting matrix metalloproteinases by e3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy</article-title><source>Semin. Cancer Biol.</source><volume>86</volume><issue>Pt 2</issue><year>2022</year><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2022.06.004</pub-id><pub-id pub-id-type="pmid">35724822</pub-id></element-citation></ref><ref id="bib59"><label>58</label><mixed-citation publication-type="other" id="sref59">T. Liu, L. Zhou, D. Li, T. Andl, Y. Zhang, Cancer-associated fibroblasts build and secure the tumor microenvironment., Front. Cell Dev. Biol. 72019) 60, <pub-id pub-id-type="doi">10.3389/fcell.2019.00060</pub-id>.<pub-id pub-id-type="pmcid">PMC6492564</pub-id><pub-id pub-id-type="pmid">31106200</pub-id></mixed-citation></ref><ref id="bib60"><label>59</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Paolillo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schinelli</surname><given-names>S.</given-names></name></person-group><article-title>Extracellular matrix alterations in metastatic processes</article-title><source>Int. J. Mol. Sci.</source><volume>20</volume><issue>19</issue><year>2019</year><pub-id pub-id-type="doi">10.3390/ijms20194947</pub-id><pub-id pub-id-type="pmcid">PMC6802000</pub-id><pub-id pub-id-type="pmid">31591367</pub-id></element-citation></ref><ref id="bib61"><label>60</label><mixed-citation publication-type="other" id="sref61">R. Rimal, P. Desai, R. Daware, et al., Cancer-associated fibroblasts: origin, function, imaging, and therapeutic targeting., Adv. Drug Deliv. Rev. 1892022) 114504, <pub-id pub-id-type="doi">10.1016/j.addr.2022.114504</pub-id>.<pub-id pub-id-type="pmid">35998825</pub-id></mixed-citation></ref><ref id="bib62"><label>61</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Kugeratski</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Neilson</surname><given-names>L.J.</given-names></name><etal/></person-group><article-title>Hypoxic cancer-associated fibroblasts increase ncbp2-as2/hiar to promote endothelial sprouting through enhanced vegf signaling</article-title><source>Sci. Signal.</source><volume>12</volume><issue>567</issue><year>2019</year><pub-id pub-id-type="doi">10.1126/scisignal.aan8247</pub-id><pub-id pub-id-type="pmcid">PMC6794160</pub-id><pub-id pub-id-type="pmid">30723174</pub-id></element-citation></ref><ref id="bib63"><label>62</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Study on the effect of type iii recombinant humanized collagen on human vascular endothelial cells., Tissue engineering. Part C</article-title><source>Methods</source><year>2023</year><pub-id pub-id-type="doi">10.1089/ten.TEC.2023.0211</pub-id><pub-id pub-id-type="pmid">38019085</pub-id></element-citation></ref><ref id="bib64"><label>63</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Eichm&#252;ller</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Osen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mandelboim</surname><given-names>O.</given-names></name><name name-style="western"><surname>Seliger</surname><given-names>B.</given-names></name></person-group><article-title>Immune modulatory micrornas involved in tumor attack and tumor immune escape</article-title><source>J. Natl. Cancer Inst.</source><volume>109</volume><issue>10</issue><year>2017</year><pub-id pub-id-type="doi">10.1093/jnci/djx034</pub-id><pub-id pub-id-type="pmid">28383653</pub-id></element-citation></ref><ref id="bib65"><label>64</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>P53 missense mutant g242a subverts natural killer cells in sheltering mouse breast cancer cells against immune rejection</article-title><source>Exp. Cell Res.</source><volume>417</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">113210</object-id><pub-id pub-id-type="doi">10.1016/j.yexcr.2022.113210</pub-id><pub-id pub-id-type="pmid">35597298</pub-id></element-citation></ref><ref id="bib66"><label>65</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Haidar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Echebli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kamau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Langsley</surname><given-names>G.</given-names></name></person-group><article-title>Transforming growth factor &#946;2 promotes transcription of cox2 and ep4, leading to a prostaglandin e2-driven autostimulatory loop that enhances virulence of theileria annulata-transformed macrophages</article-title><source>Infect. Immun.</source><volume>83</volume><issue>5</issue><year>2015</year><fpage>1869</fpage><lpage>1880</lpage><pub-id pub-id-type="doi">10.1128/IAI.02975-14</pub-id><pub-id pub-id-type="pmid">25690101</pub-id><pub-id pub-id-type="pmcid">PMC4399038</pub-id></element-citation></ref><ref id="bib67"><label>66</label><mixed-citation publication-type="other" id="sref67">M. Ermis, N. Falcone, N. Roberto De Barros, et al., Tunable hybrid hydrogels with multicellular spheroids for modeling desmoplastic pancreatic cancer., Bioact. Mater. 252023) 360-373, <pub-id pub-id-type="doi">10.1016/j.bioactmat.2023.02.005</pub-id>.<pub-id pub-id-type="pmcid">PMC9984297</pub-id><pub-id pub-id-type="pmid">36879666</pub-id></mixed-citation></ref><ref id="bib68"><label>67</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Netrin-1 promotes the immunosuppressive activity of mdscs in colorectal cancer</article-title><source>Cancer Immunol. Res.</source><volume>11</volume><issue>5</issue><year>2023</year><fpage>600</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-22-0658</pub-id><pub-id pub-id-type="pmid">36812256</pub-id></element-citation></ref><ref id="bib69"><label>68</label><mixed-citation publication-type="other" id="sref69">R. Dutta, R. Khalil, K. Mayilsamy, et al., Combination therapy of mithramycin a and immune checkpoint inhibitor for the treatment of colorectal cancer in an orthotopic murine model., Front. Immunol. 122021) 706133, <pub-id pub-id-type="doi">10.3389/fimmu.2021.706133</pub-id>.<pub-id pub-id-type="pmcid">PMC8350740</pub-id><pub-id pub-id-type="pmid">34381456</pub-id></mixed-citation></ref><ref id="bib70"><label>69</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>E.Y.</given-names></name></person-group><article-title>Refining immuno-oncology approaches in metastatic prostate cancer: transcending current limitations</article-title><source>Curr. Treat. Options Oncol.</source><volume>22</volume><issue>2</issue><year>2021</year><fpage>13</fpage><pub-id pub-id-type="doi">10.1007/s11864-020-00808-x</pub-id><pub-id pub-id-type="pmid">33433743</pub-id></element-citation></ref><ref id="bib71"><label>70</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Tim-3 signaling blockade with &#945;-lactose induces compensatory tigit expression in plasmodium berghei anka-infected mice</article-title><source>Parasites Vectors</source><volume>12</volume><issue>1</issue><year>2019</year><fpage>534</fpage><pub-id pub-id-type="doi">10.1186/s13071-019-3788-x</pub-id><pub-id pub-id-type="pmid">31711531</pub-id><pub-id pub-id-type="pmcid">PMC6849286</pub-id></element-citation></ref><ref id="bib72"><label>71</label><mixed-citation publication-type="other" id="sref72">G.S. Santiago-S&#225;nchez, J.W. Hodge, K.P. Fabian, Tipping the scales: immunotherapeutic strategies that disrupt immunosuppression and promote immune activation., Front. Immunol. 132022) 993624, <pub-id pub-id-type="doi">10.3389/fimmu.2022.993624</pub-id>.<pub-id pub-id-type="pmcid">PMC9492957</pub-id><pub-id pub-id-type="pmid">36159809</pub-id></mixed-citation></ref><ref id="bib73"><label>72</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Facciabene</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Sanctis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pierini</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy</article-title><source>OncoImmunology</source><volume>6</volume><issue>9</issue><year>2017</year><object-id pub-id-type="publisher-id">e1326442</object-id><pub-id pub-id-type="doi">10.1080/2162402X.2017.1326442</pub-id><pub-id pub-id-type="pmcid">PMC5599081</pub-id><pub-id pub-id-type="pmid">28932632</pub-id></element-citation></ref><ref id="bib74"><label>73</label><mixed-citation publication-type="other" id="sref74">Journal/author name estimator, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://jane.biosemantics.org/suggestions.php" id="intref0120">https://jane.biosemantics.org/suggestions.php</ext-link> (accessed 2024/January/28).</mixed-citation></ref><ref id="bib75"><label>74</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>O'Donnell</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>M.W.L.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>M.J.</given-names></name></person-group><article-title>Cancer immunoediting and resistance to t cell-based immunotherapy</article-title><source>Nat. Rev. Clin. Oncol.</source><volume>16</volume><issue>3</issue><year>2019</year><fpage>151</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1038/s41571-018-0142-8</pub-id><pub-id pub-id-type="pmid">30523282</pub-id></element-citation></ref><ref id="bib76"><label>75</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Old</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>R.D.</given-names></name></person-group><article-title>Cancer immunoediting: from immunosurveillance to tumor escape</article-title><source>Nat. Immunol.</source><volume>3</volume><issue>11</issue><year>2002</year><fpage>991</fpage><lpage>998</lpage><pub-id pub-id-type="pmid">12407406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni1102-991</pub-id></element-citation></ref><ref id="bib77"><label>76</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Schreiber</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Old</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>M.J.</given-names></name></person-group><article-title>Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion</article-title><source>Science (New York, N.Y.)</source><volume>331</volume><issue>6024</issue><year>2011</year><fpage>1565</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1126/science.1203486</pub-id><pub-id pub-id-type="pmid">21436444</pub-id></element-citation></ref><ref id="bib78"><label>77</label><mixed-citation publication-type="other" id="sref78">J. Liu, R. Piranlioglu, F. Ye, K. Shu, T. Lei, H. Nakashima, Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions., Front. Cell. Infect. Microbiol. 132023) 1141034, <pub-id pub-id-type="doi">10.3389/fcimb.2023.1141034</pub-id>.<pub-id pub-id-type="pmcid">PMC10206241</pub-id><pub-id pub-id-type="pmid">37234776</pub-id></mixed-citation></ref><ref id="bib79"><label>78</label><mixed-citation publication-type="other" id="sref79">D.R. Principe, L. Chiec, N.A. Mohindra, H.G. Munshi, Regulatory t-cells as an emerging barrier to immune checkpoint inhibition in lung cancer., Front. Oncol. 112021) 684098, <pub-id pub-id-type="doi">10.3389/fonc.2021.684098</pub-id>.<pub-id pub-id-type="pmcid">PMC8204014</pub-id><pub-id pub-id-type="pmid">34141625</pub-id></mixed-citation></ref><ref id="bib80"><label>79</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Kumagai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Togashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kamada</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The pd-1 expression balance between effector and regulatory t cells predicts the clinical efficacy of pd-1 blockade therapies</article-title><source>Nat. Immunol.</source><volume>21</volume><issue>11</issue><year>2020</year><fpage>1346</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0769-3</pub-id><pub-id pub-id-type="pmid">32868929</pub-id></element-citation></ref><ref id="bib81"><label>80</label><mixed-citation publication-type="other" id="sref81">R. Saleh, E. Elkord, Treg-mediated acquired resistance to immune checkpoint inhibitors., Cancer Lett. 4572019) 168-179, <pub-id pub-id-type="doi">10.1016/j.canlet.2019.05.003</pub-id>.<pub-id pub-id-type="pmid">31078738</pub-id></mixed-citation></ref><ref id="bib82"><label>81</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Veglia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sanseviero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gabrilovich</surname><given-names>D.I.</given-names></name></person-group><article-title>Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity</article-title><source>Nat. Rev. Immunol.</source><volume>21</volume><issue>8</issue><year>2021</year><fpage>485</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00490-y</pub-id><pub-id pub-id-type="pmid">33526920</pub-id><pub-id pub-id-type="pmcid">PMC7849958</pub-id></element-citation></ref><ref id="bib83"><label>82</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Allard</surname><given-names>B.</given-names></name><name name-style="western"><surname>Longhi</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Robson</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Stagg</surname><given-names>J.</given-names></name></person-group><article-title>The ectonucleotidases cd39 and cd73: novel checkpoint inhibitor targets</article-title><source>Immunol. Rev.</source><volume>276</volume><issue>1</issue><year>2017</year><fpage>121</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1111/imr.12528</pub-id><pub-id pub-id-type="pmid">28258700</pub-id><pub-id pub-id-type="pmcid">PMC5338647</pub-id></element-citation></ref><ref id="bib84"><label>83</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Cd39/cd73 upregulation on myeloid-derived suppressor cells via tgf-&#946;-mtor-hif-1 signaling in patients with non-small cell lung cancer</article-title><source>OncoImmunology</source><volume>6</volume><issue>6</issue><year>2017</year><object-id pub-id-type="publisher-id">e1320011</object-id><pub-id pub-id-type="doi">10.1080/2162402X.2017.1320011</pub-id><pub-id pub-id-type="pmcid">PMC5486179</pub-id><pub-id pub-id-type="pmid">28680754</pub-id></element-citation></ref><ref id="bib85"><label>84</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Myeloid-derived suppressor cells promote lung cancer metastasis by ccl11 to activate erk and akt signaling and induce epithelial-mesenchymal transition in tumor cells</article-title><source>Oncogene</source><volume>40</volume><issue>8</issue><year>2021</year><fpage>1476</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-01605-4</pub-id><pub-id pub-id-type="pmid">33452453</pub-id></element-citation></ref><ref id="bib86"><label>85</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Salehi-Rad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Crosson</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Inhibition of granulocytic myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in lkb1-deficient non-small cell lung cancer</article-title><source>Cancer Res.</source><volume>81</volume><issue>12</issue><year>2021</year><fpage>3295</fpage><lpage>3308</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-3564</pub-id><pub-id pub-id-type="pmid">33853830</pub-id><pub-id pub-id-type="pmcid">PMC8776246</pub-id></element-citation></ref><ref id="bib87"><label>86</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Orillion</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Damayanti</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of pd-1 inhibition in murine models of lung and renal cell carcinoma</article-title><source>Clin. Cancer Res. : an official journal of the American Association for Cancer Research</source><volume>23</volume><issue>17</issue><year>2017</year><fpage>5187</fpage><lpage>5201</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0741</pub-id><pub-id pub-id-type="pmcid">PMC5723438</pub-id><pub-id pub-id-type="pmid">28698201</pub-id></element-citation></ref><ref id="bib88"><label>87</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Lo Russo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sommariva</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Antibody-fc/fcr interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to pd-1/pd-l1 blockade</article-title><source>Clin. Cancer Res. : an official journal of the American Association for Cancer Research</source><volume>25</volume><issue>3</issue><year>2019</year><fpage>989</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1390</pub-id><pub-id pub-id-type="pmid">30206165</pub-id></element-citation></ref><ref id="bib89"><label>88</label><mixed-citation publication-type="other" id="sref89">L. Li, G. Lu, Y. Liu, et al., Low infiltration of cd8+ pd-l1+ t cells and m2 macrophages predicts improved clinical outcomes after immune checkpoint inhibitor therapy in non-small cell lung carcinoma., Front. Oncol. 112021) 658690, <pub-id pub-id-type="doi">10.3389/fonc.2021.658690</pub-id>.<pub-id pub-id-type="pmcid">PMC8213070</pub-id><pub-id pub-id-type="pmid">34150625</pub-id></mixed-citation></ref><ref id="bib90"><label>89</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zugazagoitia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>F.S.</given-names></name><etal/></person-group><article-title>Immune cell pd-l1 colocalizes with macrophages and is associated with outcome in pd-1 pathway blockade therapy</article-title><source>Clin. Cancer Res. : an official journal of the American Association for Cancer Research</source><volume>26</volume><issue>4</issue><year>2020</year><fpage>970</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1040</pub-id><pub-id pub-id-type="pmcid">PMC7024671</pub-id><pub-id pub-id-type="pmid">31615933</pub-id></element-citation></ref><ref id="bib91"><label>90</label><mixed-citation publication-type="other" id="sref91">J. Kargl, S.E. Busch, G.H.Y. Yang, et al., Neutrophils dominate the immune cell composition in non-small cell lung cancer., Nat. Commun. 82017) 14381, <pub-id pub-id-type="doi">10.1038/ncomms14381</pub-id>.<pub-id pub-id-type="pmcid">PMC5296654</pub-id><pub-id pub-id-type="pmid">28146145</pub-id></mixed-citation></ref><ref id="bib92"><label>91</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Aloe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vlahos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Irving</surname><given-names>L.</given-names></name><name name-style="western"><surname>Steinfort</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bozinovski</surname><given-names>S.</given-names></name></person-group><article-title>Emerging and multifaceted role of neutrophils in lung cancer</article-title><source>Transl. Lung Cancer Res.</source><volume>10</volume><issue>6</issue><year>2021</year><fpage>2806</fpage><lpage>2818</lpage><pub-id pub-id-type="doi">10.21037/tlcr-20-760</pub-id><pub-id pub-id-type="pmid">34295679</pub-id><pub-id pub-id-type="pmcid">PMC8264329</pub-id></element-citation></ref><ref id="bib93"><label>92</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Akbay</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Interleukin-17a promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to pd-1 blockade</article-title><source>J. Thorac. Oncol. : official publication of the International Association for the Study of Lung Cancer</source><volume>12</volume><issue>8</issue><year>2017</year><fpage>1268</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2017.04.017</pub-id><pub-id pub-id-type="pmcid">PMC5532066</pub-id><pub-id pub-id-type="pmid">28483607</pub-id></element-citation></ref><ref id="bib95"><label>93</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Ohta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sakoda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tamada</surname><given-names>K.</given-names></name></person-group><article-title>Novel technologies for improving the safety and efficacy of car-t cell therapy</article-title><source>Int. J. Hematol.</source><volume>117</volume><issue>5</issue><year>2023</year><fpage>647</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1007/s12185-022-03478-7</pub-id><pub-id pub-id-type="pmid">36309630</pub-id></element-citation></ref><ref id="bib96"><label>94</label><mixed-citation publication-type="other" id="sref96">Z. Qi, X. Long, J. Liu, P. Cheng, Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy., Front. Cell. Neurosci. 162022) 819363, <pub-id pub-id-type="doi">10.3389/fncel.2022.819363</pub-id>.<pub-id pub-id-type="pmcid">PMC9507431</pub-id><pub-id pub-id-type="pmid">36159398</pub-id></mixed-citation></ref><ref id="bib97"><label>95</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name></person-group><article-title>Glucocorticoids are double-edged sword in the treatment of covid-19 and cancers</article-title><source>Int. J. Biol. Sci.</source><volume>17</volume><issue>6</issue><year>2021</year><fpage>1530</fpage><lpage>1537</lpage><pub-id pub-id-type="doi">10.7150/ijbs.58695</pub-id><pub-id pub-id-type="pmid">33907516</pub-id><pub-id pub-id-type="pmcid">PMC8071771</pub-id></element-citation></ref><ref id="bib98"><label>96</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>J.</given-names></name></person-group><article-title>Neuroendocrine control of appetite and metabolism</article-title><source>Exp. Mol. Med.</source><volume>53</volume><issue>4</issue><year>2021</year><fpage>505</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1038/s12276-021-00597-9</pub-id><pub-id pub-id-type="pmid">33837263</pub-id><pub-id pub-id-type="pmcid">PMC8102538</pub-id></element-citation></ref><ref id="bib99"><label>97</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Michalek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goj</surname><given-names>T.</given-names></name><name name-style="western"><surname>Plazzo</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Marovca</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bornhauser</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>T.</given-names></name></person-group><article-title>Lrh-1/nr5a2 interacts with the glucocorticoid receptor to regulate glucocorticoid resistance</article-title><source>EMBO Rep.</source><volume>23</volume><issue>9</issue><year>2022</year><object-id pub-id-type="publisher-id">e54195</object-id><pub-id pub-id-type="doi">10.15252/embr.202154195</pub-id><pub-id pub-id-type="pmcid">PMC9442305</pub-id><pub-id pub-id-type="pmid">35801407</pub-id></element-citation></ref><ref id="bib100"><label>98</label><mixed-citation publication-type="other" id="sref100">A. Shimba, K. Ikuta, Glucocorticoids regulate circadian rhythm of innate and adaptive immunity., Front. Immunol. 112020) 2143, <pub-id pub-id-type="doi">10.3389/fimmu.2020.02143</pub-id>.<pub-id pub-id-type="pmcid">PMC7533542</pub-id><pub-id pub-id-type="pmid">33072078</pub-id></mixed-citation></ref><ref id="bib101"><label>99</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Noncanonical functions of glucocorticoids: a novel role for glucocorticoids in performing multiple beneficial functions in endometrial stem cells</article-title><source>Cell Death Dis.</source><volume>12</volume><issue>6</issue><year>2021</year><fpage>612</fpage><pub-id pub-id-type="doi">10.1038/s41419-021-03893-4</pub-id><pub-id pub-id-type="pmid">34120144</pub-id><pub-id pub-id-type="pmcid">PMC8197759</pub-id></element-citation></ref><ref id="bib102"><label>100</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Tim-3 downregulation by toxoplasma gondii infection contributes to decidual dendritic cell dysfunction</article-title><source>Parasites Vectors</source><volume>15</volume><issue>1</issue><year>2022</year><fpage>393</fpage><pub-id pub-id-type="doi">10.1186/s13071-022-05506-1</pub-id><pub-id pub-id-type="pmid">36303229</pub-id><pub-id pub-id-type="pmcid">PMC9615254</pub-id></element-citation></ref><ref id="bib103"><label>101</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Le&#243;n</surname><given-names>B.</given-names></name></person-group><article-title>A model of th2 differentiation based on polarizing cytokine repression</article-title><source>Trends Immunol.</source><volume>44</volume><issue>6</issue><year>2023</year><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.it.2023.04.004</pub-id><pub-id pub-id-type="pmid">37100645</pub-id><pub-id pub-id-type="pmcid">PMC10219849</pub-id></element-citation></ref><ref id="bib104"><label>102</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Targeting regulatory t cells for immunotherapy in melanoma</article-title><source>Molecular biomedicine</source><volume>2</volume><issue>1</issue><year>2021</year><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s43556-021-00038-z</pub-id><pub-id pub-id-type="pmid">34806028</pub-id><pub-id pub-id-type="pmcid">PMC8591697</pub-id></element-citation></ref><ref id="bib105"><label>103</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>The high-expression programming of sr-b1 mediates adrenal dysfunction in female offspring induced by prenatal caffeine exposure and its cholesterol accumulation mechanism</article-title><source>Food Funct.</source><volume>15</volume><issue>2</issue><year>2024</year><fpage>716</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1039/d3fo03561a</pub-id><pub-id pub-id-type="pmid">38113052</pub-id></element-citation></ref><ref id="bib106"><label>104</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Amweg</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Detection and activity of 11 beta hydroxylase (cyp11b1) in the bovine ovary</article-title><source>Reproduction (Cambridge, England)</source><volume>153</volume><issue>4</issue><year>2017</year><fpage>433</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1530/REP-16-0493</pub-id><pub-id pub-id-type="pmid">28069904</pub-id></element-citation></ref><ref id="bib107"><label>105</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Terao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>I.</given-names></name></person-group><article-title>Local cortisol/corticosterone activation in skin physiology and pathology</article-title><source>J. Dermatol. Sci.</source><volume>84</volume><issue>1</issue><year>2016</year><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2016.06.014</pub-id><pub-id pub-id-type="pmid">27431412</pub-id></element-citation></ref><ref id="bib108"><label>106</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Poinot</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dupuychaffray</surname><given-names>E.</given-names></name><name name-style="western"><surname>Arnoux</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Activation of endogenous glucocorticoids by hsd11b1 inhibits the antitumor immune response in renal cancer</article-title><source>OncoImmunology</source><volume>13</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">2286820</object-id><pub-id pub-id-type="doi">10.1080/2162402X.2023.2286820</pub-id><pub-id pub-id-type="pmcid">PMC10761155</pub-id><pub-id pub-id-type="pmid">38170044</pub-id></element-citation></ref><ref id="bib109"><label>107</label><mixed-citation publication-type="other" id="sref109">M. Kley, S.O. Moser, D.V. Winter, A. Odermatt, In vitro methods to assess 11&#946;-hydroxysteroid dehydrogenase type 1 activity., Methods Enzymol. 6892023) 121-165, <pub-id pub-id-type="doi">10.1016/bs.mie.2023.04.004</pub-id>.<pub-id pub-id-type="pmid">37802569</pub-id></mixed-citation></ref><ref id="bib110"><label>108</label><mixed-citation publication-type="other" id="sref110">R. Himmelstein, A. Spahija, H.B. Fokidis, Evidence for fasting induced extra-adrenal steroidogenesis in the male brown anole, anolis sagrei., Comparative biochemistry and physiology. Part B, Biochemistry &amp; molecular biology 2532021) 110544, <pub-id pub-id-type="doi">10.1016/j.cbpb.2020.110544</pub-id>.<pub-id pub-id-type="pmid">33338607</pub-id></mixed-citation></ref><ref id="bib111"><label>109</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Swarbrick</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Seibel</surname><given-names>M.</given-names></name></person-group><article-title>Mechanisms in endocrinology: local and systemic effects of glucocorticoids on metabolism: new lessons from animal models</article-title><source>Eur. J. Endocrinol.</source><volume>185</volume><issue>5</issue><year>2021</year><fpage>R113</fpage><lpage>R129</lpage><pub-id pub-id-type="doi">10.1530/EJE-21-0553</pub-id><pub-id pub-id-type="pmid">34478405</pub-id></element-citation></ref><ref id="bib112"><label>110</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>N.</given-names></name></person-group><article-title>Steroid hormone regulation of immune responses in cancer</article-title><source>Immunometabolism</source><volume>4</volume><issue>4</issue><year>2022</year><fpage>e12</fpage><pub-id pub-id-type="doi">10.1097/IN9.0000000000000012</pub-id><pub-id pub-id-type="pmcid">PMC9622373</pub-id><pub-id pub-id-type="pmid">36337733</pub-id></element-citation></ref><ref id="bib113"><label>111</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Ronchetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Migliorati</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bruscoli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Riccardi</surname><given-names>C.</given-names></name></person-group><article-title>Defining the role of glucocorticoids in inflammation</article-title><source>Clin. Sci.</source><volume>132</volume><issue>14</issue><year>2018</year><fpage>1529</fpage><lpage>1543</lpage><pub-id pub-id-type="doi">10.1042/CS20171505</pub-id><pub-id pub-id-type="pmid">30065045</pub-id></element-citation></ref><ref id="bib114"><label>112</label><mixed-citation publication-type="other" id="sref114">Y. Wang, Y. Zhang, J. Hu, et al., Glucocorticoids modulate neural activity via a rapid non-genomic effect on kv2.2 channels in the central nervous system., Neurobiol. Stress 282024) 100593, <pub-id pub-id-type="doi">10.1016/j.ynstr.2023.100593</pub-id>.<pub-id pub-id-type="pmcid">PMC10698577</pub-id><pub-id pub-id-type="pmid">38075025</pub-id></mixed-citation></ref><ref id="bib115"><label>113</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Abulizi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Camporez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jurczak</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Adipose glucocorticoid action influences whole-body metabolism via modulation of hepatic insulin action</article-title><source>Faseb. J.</source><volume>33</volume><issue>7</issue><year>2019</year><fpage>8174</fpage><lpage>8185</lpage><pub-id pub-id-type="doi">10.1096/fj.201802706R</pub-id><comment>official publication of the Federation of American Societies for Experimental Biology</comment><pub-id pub-id-type="pmid">30922125</pub-id><pub-id pub-id-type="pmcid">PMC6593882</pub-id></element-citation></ref><ref id="bib116"><label>114</label><mixed-citation publication-type="other" id="sref116">Z. Alimardan, M. Abbasi, F. Hasanzadeh, M. Aghaei, G. Khodarahmi, K. Kashfi, Heat shock proteins and cancer: the foxm1 connection., Biochem. Pharmacol. 2112023) 115505, <pub-id pub-id-type="doi">10.1016/j.bcp.2023.115505</pub-id>.<pub-id pub-id-type="pmcid">PMC10134075</pub-id><pub-id pub-id-type="pmid">36931349</pub-id></mixed-citation></ref><ref id="bib117"><label>115</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Gaur</surname><given-names>D.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Guleria</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>D.</given-names></name></person-group><article-title>The yeast hsp70 cochaperone ydj1 regulates functional distinction of ssa hsp70s in the hsp90 chaperoning pathway</article-title><source>Genetics</source><volume>215</volume><issue>3</issue><year>2020</year><fpage>683</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1534/genetics.120.303190</pub-id><pub-id pub-id-type="pmid">32299842</pub-id><pub-id pub-id-type="pmcid">PMC7337085</pub-id></element-citation></ref><ref id="bib118"><label>116</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Zeyen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Seternes</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Mikkola</surname><given-names>I.</given-names></name></person-group><article-title>Crosstalk between p38 mapk and gr signaling</article-title><source>Int. J. Mol. Sci.</source><volume>23</volume><issue>6</issue><year>2022</year><pub-id pub-id-type="doi">10.3390/ijms23063322</pub-id><pub-id pub-id-type="pmcid">PMC8953609</pub-id><pub-id pub-id-type="pmid">35328742</pub-id></element-citation></ref><ref id="bib119"><label>117</label><mixed-citation publication-type="other" id="sref119">L.M. Harrison, J.G. Tasker, Multiplexed membrane signaling by glucocorticoids., Current opinion in endocrine and metabolic research 262022), <pub-id pub-id-type="doi">10.1016/j.coemr.2022.100390</pub-id>.<pub-id pub-id-type="pmcid">PMC10703063</pub-id><pub-id pub-id-type="pmid">38075196</pub-id></mixed-citation></ref><ref id="bib120"><label>118</label><mixed-citation publication-type="other" id="sref120">R.F. Candia, L.S. Cohen, V. Morozova, C. Corbo, A.D. Alonso, Importin-mediated pathological tau nuclear translocation causes disruption of the nuclear lamina, tdp-43 mislocalization and cell death., Front. Mol. Neurosci. 152022) 888420, <pub-id pub-id-type="doi">10.3389/fnmol.2022.888420</pub-id>.<pub-id pub-id-type="pmcid">PMC9113199</pub-id><pub-id pub-id-type="pmid">35592115</pub-id></mixed-citation></ref><ref id="bib121"><label>119</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Kulik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bothe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kibar</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared dna binding sites</article-title><source>Nucleic Acids Res.</source><volume>49</volume><issue>7</issue><year>2021</year><fpage>3856</fpage><lpage>3875</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab185</pub-id><pub-id pub-id-type="pmid">33751115</pub-id><pub-id pub-id-type="pmcid">PMC8053126</pub-id></element-citation></ref><ref id="bib122"><label>120</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Noughabi</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Matin</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Farshchian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bahrami</surname><given-names>A.R.</given-names></name></person-group><article-title>Immunomodulatory properties of mouse mesenchymal stromal/stem cells upon ectopic expression of immunoregulator nanos2</article-title><source>Stem Cell Rev. Rep.</source><volume>19</volume><issue>3</issue><year>2023</year><fpage>734</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1007/s12015-022-10451-8</pub-id><pub-id pub-id-type="pmid">36348161</pub-id></element-citation></ref><ref id="bib123"><label>121</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Greulich</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wierer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mechtidou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonzalez-Garcia</surname><given-names>O.</given-names></name><name name-style="western"><surname>Uhlenhaut</surname><given-names>N.H.</given-names></name></person-group><article-title>The glucocorticoid receptor recruits the compass complex to regulate inflammatory transcription at macrophage enhancers</article-title><source>Cell Rep.</source><volume>34</volume><issue>6</issue><year>2021</year><object-id pub-id-type="publisher-id">108742</object-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108742</pub-id><pub-id pub-id-type="pmcid">PMC7873837</pub-id><pub-id pub-id-type="pmid">33567280</pub-id></element-citation></ref><ref id="bib124"><label>122</label><mixed-citation publication-type="other" id="sref124">Z. Lee, T. Tran, Genomic and non-genomic effects of glucocorticoids in respiratory diseases., Adv. Pharmacol. 982023) 1-30, <pub-id pub-id-type="doi">10.1016/bs.apha.2023.04.006</pub-id>.<pub-id pub-id-type="pmid">37524484</pub-id></mixed-citation></ref><ref id="bib125"><label>123</label><mixed-citation publication-type="other" id="sref125">M. Tena-Garitaonaindia, M. Arredondo-Amador, C. Mascaraque, et al., Modulation of intestinal barrier function by glucocorticoids: lessons from preclinical models., Pharmacol. Res. 1772022) 106056, <pub-id pub-id-type="doi">10.1016/j.phrs.2022.106056</pub-id>.<pub-id pub-id-type="pmid">34995794</pub-id></mixed-citation></ref><ref id="bib126"><label>124</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Horiguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kadomatsu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Angptl2 promotes immune checkpoint inhibitor-related murine autoimmune myocarditis</article-title><source>Commun. Biol.</source><volume>6</volume><issue>1</issue><year>2023</year><fpage>965</fpage><pub-id pub-id-type="doi">10.1038/s42003-023-05338-4</pub-id><pub-id pub-id-type="pmid">37736764</pub-id><pub-id pub-id-type="pmcid">PMC10517162</pub-id></element-citation></ref><ref id="bib127"><label>125</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Willsmore</surname><given-names>Z.N.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Regulatory b cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade</article-title><source>Nat. Commun.</source><volume>13</volume><issue>1</issue><year>2022</year><fpage>3148</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-30863-x</pub-id><pub-id pub-id-type="pmid">35672305</pub-id><pub-id pub-id-type="pmcid">PMC9174492</pub-id></element-citation></ref><ref id="bib128"><label>126</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>van Eijs</surname><given-names>M.J.M.</given-names></name><name name-style="western"><surname>Verheijden</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>van der Wees</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Toxicity-specific peripheral blood t and b cell dynamics in anti-pd-1 and combined immune checkpoint inhibition</article-title><source>Cancer Immunol. Immunother. : CII</source><volume>72</volume><issue>12</issue><year>2023</year><fpage>4049</fpage><lpage>4064</lpage><pub-id pub-id-type="doi">10.1007/s00262-023-03541-0</pub-id><pub-id pub-id-type="pmid">37794264</pub-id><pub-id pub-id-type="pmcid">PMC10700442</pub-id></element-citation></ref><ref id="bib129"><label>127</label><mixed-citation publication-type="other" id="sref129">B. Gosangi, Y. Wang, A.N. Rubinowitz, et al., Cardiothoracic complications of immune checkpoint inhibitors., Clin. Imaging 1022023) 98-108, <pub-id pub-id-type="doi">10.1016/j.clinimag.2023.08.001</pub-id>.<pub-id pub-id-type="pmid">37659356</pub-id></mixed-citation></ref><ref id="bib130"><label>128</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Teng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name></person-group><article-title>Molecular mechanisms of cutaneous immune-related adverse events (iraes) induced by immune checkpoint inhibitors</article-title><source>Curr. Oncol.</source><volume>30</volume><issue>7</issue><year>2023</year><fpage>6805</fpage><lpage>6819</lpage><pub-id pub-id-type="doi">10.3390/curroncol30070498</pub-id><pub-id pub-id-type="pmid">37504358</pub-id><pub-id pub-id-type="pmcid">PMC10378098</pub-id></element-citation></ref><ref id="bib131"><label>129</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Kubin</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Hellberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Palatsi</surname><given-names>R.</given-names></name></person-group><article-title>Glucocorticoids: the mode of action in bullous pemphigoid</article-title><source>Exp. Dermatol.</source><volume>26</volume><issue>12</issue><year>2017</year><fpage>1253</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1111/exd.13408</pub-id><pub-id pub-id-type="pmid">28771827</pub-id></element-citation></ref><ref id="bib132"><label>130</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Ingawale</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Mandlik</surname><given-names>S.K.</given-names></name></person-group><article-title>New insights into the novel anti-inflammatory mode of action of glucocorticoids</article-title><source>Immunopharmacol. Immunotoxicol.</source><volume>42</volume><issue>2</issue><year>2020</year><fpage>59</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1080/08923973.2020.1728765</pub-id><pub-id pub-id-type="pmid">32070175</pub-id></element-citation></ref><ref id="bib133"><label>131</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Kelley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vander Molen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Impact of glucocorticoids on cardiovascular system-the yin yang effect</article-title><source>J. Personalized Med.</source><volume>12</volume><issue>11</issue><year>2022</year><pub-id pub-id-type="doi">10.3390/jpm12111829</pub-id><pub-id pub-id-type="pmcid">PMC9694205</pub-id><pub-id pub-id-type="pmid">36579545</pub-id></element-citation></ref><ref id="bib134"><label>132</label><element-citation publication-type="book" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Kurematsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mohri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y.</given-names></name></person-group><part-title>Adrenal Crisis Associated with Covid-19 Vaccination in Patients with Adrenal Insufficiency</part-title><year>2023</year><pub-id pub-id-type="doi">10.1210/jcemcr/luad079</pub-id><comment>luad79</comment><pub-id pub-id-type="pmcid">PMC10580477</pub-id><pub-id pub-id-type="pmid">37908998</pub-id></element-citation></ref><ref id="bib135"><label>133</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Iijima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Motono</surname><given-names>N.</given-names></name><name name-style="western"><surname>Uramoto</surname><given-names>H.</given-names></name></person-group><article-title>Bilateral adrenal infarction and insufficiency associated with antiphospholipid syndrome and surgery: a case report</article-title><source>Internet J. Emerg. Med.</source><volume>16</volume><issue>1</issue><year>2023</year><fpage>93</fpage><pub-id pub-id-type="doi">10.1186/s12245-023-00575-0</pub-id><pub-id pub-id-type="pmcid">PMC10734168</pub-id><pub-id pub-id-type="pmid">38129772</pub-id></element-citation></ref><ref id="bib136"><label>134</label><mixed-citation publication-type="other" id="sref136">Y. Wang, X. Liu, P. Xia, et al., The regulatory role of micrornas on phagocytes: a potential therapeutic target for chronic diseases., Front. Immunol. 132022) 901166, <pub-id pub-id-type="doi">10.3389/fimmu.2022.901166</pub-id>.<pub-id pub-id-type="pmcid">PMC9130478</pub-id><pub-id pub-id-type="pmid">35634335</pub-id></mixed-citation></ref><ref id="bib137"><label>135</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Single-cell transcriptomics reveals distinct cell response between acute and chronic pulmonary infection of pseudomonas aeruginosa</article-title><source>MedComm</source><volume>3</volume><issue>4</issue><year>2022</year><fpage>e193</fpage><pub-id pub-id-type="doi">10.1002/mco2.193</pub-id><pub-id pub-id-type="pmid">36514779</pub-id><pub-id pub-id-type="pmcid">PMC9732387</pub-id></element-citation></ref><ref id="bib138"><label>136</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Kalfeist</surname><given-names>L.</given-names></name><name name-style="western"><surname>Galland</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ledys</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ghiringhelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Limagne</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ladoire</surname><given-names>S.</given-names></name></person-group><article-title>Impact of glucocorticoid use in oncology in the immunotherapy era</article-title><source>Cells</source><volume>11</volume><issue>5</issue><year>2022</year><pub-id pub-id-type="doi">10.3390/cells11050770</pub-id><pub-id pub-id-type="pmcid">PMC8909189</pub-id><pub-id pub-id-type="pmid">35269392</pub-id></element-citation></ref><ref id="bib139"><label>137</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Braegelmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Niebel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>J.</given-names></name></person-group><article-title>Targeted therapies in autoimmune skin diseases</article-title><source>J. Invest. Dermatol.</source><volume>142</volume><issue>3 Pt B</issue><year>2022</year><fpage>969</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2021.08.439</pub-id><pub-id pub-id-type="pmid">34756580</pub-id></element-citation></ref><ref id="bib140"><label>138</label><mixed-citation publication-type="other" id="sref140">I. Muscari, A. Fierabracci, S. Adorisio, et al., Glucocorticoids and natural killer cells: a suppressive relationship., Biochem. Pharmacol. 1982022) 114930, <pub-id pub-id-type="doi">10.1016/j.bcp.2022.114930</pub-id>.<pub-id pub-id-type="pmid">35149054</pub-id></mixed-citation></ref><ref id="bib141"><label>139</label><mixed-citation publication-type="other" id="sref141">D. Elieh Ali Komi, D. Ribatti, Mast cell-mediated mechanistic pathways in organ transplantation., Eur. J. Pharmacol. 8572019) 172458, <pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172458</pub-id>.<pub-id pub-id-type="pmid">31202799</pub-id></mixed-citation></ref><ref id="bib142"><label>140</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Mundisugih</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fernando</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bergin</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A single-center experience of the optimal initial immunosuppressive strategy for preventing early acute cellular rejection in orthotopic heart transplantation associated with renal dysfunction</article-title><source>Prog. Transplant.</source><volume>29</volume><issue>4</issue><year>2019</year><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1177/1526924819873908</pub-id><pub-id pub-id-type="pmid">31476958</pub-id></element-citation></ref><ref id="bib143"><label>141</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-Jimenez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Petrillo</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Busada</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Hermoso</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cidlowski</surname><given-names>J.A.</given-names></name></person-group><article-title>Glucocorticoids mobilize macrophages by transcriptionally up-regulating the exopeptidase dpp4</article-title><source>J. Biol. Chem.</source><volume>295</volume><issue>10</issue><year>2020</year><fpage>3213</fpage><lpage>3227</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.010894</pub-id><pub-id pub-id-type="pmid">31988243</pub-id><pub-id pub-id-type="pmcid">PMC7062181</pub-id></element-citation></ref><ref id="bib144"><label>142</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Gene regulation in animal mirna biogenesis</article-title><source>Epigenomics</source><year>2022</year><pub-id pub-id-type="doi">10.2217/epi-2022-0214</pub-id><pub-id pub-id-type="pmid">36382497</pub-id></element-citation></ref><ref id="bib145"><label>143</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Strokotova</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Grigorieva</surname><given-names>E.V.</given-names></name></person-group><article-title>Glucocorticoid effects on proteoglycans and glycosaminoglycans</article-title><source>Int. J. Mol. Sci.</source><volume>23</volume><issue>24</issue><year>2022</year><pub-id pub-id-type="doi">10.3390/ijms232415678</pub-id><pub-id pub-id-type="pmcid">PMC9778983</pub-id><pub-id pub-id-type="pmid">36555315</pub-id></element-citation></ref><ref id="bib146"><label>144</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>Priori</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mastromanno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Izzo</surname><given-names>R.</given-names></name></person-group><article-title>What about glucocorticoids in primary sj&#246;gren's syndrome?</article-title><source>Clin. Exp. Rheumatol.</source><volume>38</volume><issue>4</issue><year>2020</year><fpage>237</fpage><lpage>244</lpage><comment>Suppl 126</comment><pub-id pub-id-type="pmid">33095141</pub-id></element-citation></ref><ref id="bib147"><label>145</label><mixed-citation publication-type="other" id="sref147">L. Ji, S. Xu, H. Luo, F. Zeng, Insights from dock2 in cell function and pathophysiology., Front. Mol. Biosci. 92022) 997659, <pub-id pub-id-type="doi">10.3389/fmolb.2022.997659</pub-id>.<pub-id pub-id-type="pmcid">PMC9559381</pub-id><pub-id pub-id-type="pmid">36250020</pub-id></mixed-citation></ref><ref id="bib148"><label>146</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Effects of glucocorticoids on leukocytes: genomic and non-genomic mechanisms</article-title><source>World J. Clin. Cases</source><volume>10</volume><issue>21</issue><year>2022</year><fpage>7187</fpage><lpage>7194</lpage><pub-id pub-id-type="doi">10.12998/wjcc.v10.i21.7187</pub-id><pub-id pub-id-type="pmid">36158016</pub-id><pub-id pub-id-type="pmcid">PMC9353929</pub-id></element-citation></ref><ref id="bib149"><label>147</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Shimba</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ikuta</surname><given-names>K.</given-names></name></person-group><article-title>Control of immunity by glucocorticoids in health and disease</article-title><source>Semin. Immunopathol.</source><volume>42</volume><issue>6</issue><year>2020</year><fpage>669</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1007/s00281-020-00827-8</pub-id><pub-id pub-id-type="pmid">33219395</pub-id></element-citation></ref><ref id="bib150"><label>148</label><mixed-citation publication-type="other" id="sref150">A.R. Fernandes, T. Dos Santos, P.L. Granja, et al., Permeability, anti-inflammatory and anti-vegf profiles of steroidal-loaded cationic nanoemulsions in retinal pigment epithelial cells under oxidative stress., Int. J. Pharm. 6172022) 121615, <pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.121615</pub-id>.<pub-id pub-id-type="pmid">35217072</pub-id></mixed-citation></ref><ref id="bib151"><label>149</label><mixed-citation publication-type="other" id="sref151">Y. Zhang, Y. Guo, W. Wei, Z. Zhang, X. Xu, Metabolomics profiling reveals berberine-inhibited inflammatory response in human gingival fibroblasts by regulating the lps-induced apoptosis signaling pathway., Front. Pharmacol. 132022) 940224, <pub-id pub-id-type="doi">10.3389/fphar.2022.940224</pub-id>.<pub-id pub-id-type="pmcid">PMC9441553</pub-id><pub-id pub-id-type="pmid">36071855</pub-id></mixed-citation></ref><ref id="bib152"><label>150</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Ribatti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tamma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ruggieri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Annese</surname><given-names>T.</given-names></name><name name-style="western"><surname>Marzullo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crivellato</surname><given-names>E.</given-names></name></person-group><article-title>Mast cells and primary systemic vasculitides</article-title><source>Microcirculation (New York, N.Y.</source><volume>25</volume><issue>8</issue><year>1994</year><object-id pub-id-type="publisher-id">e12498</object-id><pub-id pub-id-type="doi">10.1111/micc.12498</pub-id><comment>2018</comment><pub-id pub-id-type="pmid">30120855</pub-id></element-citation></ref><ref id="bib153"><label>151</label><mixed-citation publication-type="other" id="sref153">Q. Shang, X. Yu, Q. Sun, H. Li, C. Sun, L. Liu, Polysaccharides regulate th1/th2 balance: a new strategy for tumor immunotherapy., Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie 1702024) 115976, <pub-id pub-id-type="doi">10.1016/j.biopha.2023.115976</pub-id>.<pub-id pub-id-type="pmid">38043444</pub-id></mixed-citation></ref><ref id="bib154"><label>152</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Adipose extracellular matrix promotes skin wound healing by inducing the differentiation of adipose-derived stem cells into fibroblasts</article-title><source>Int. J. Mol. Med.</source><volume>43</volume><issue>2</issue><year>2019</year><fpage>890</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2018.4006</pub-id><pub-id pub-id-type="pmid">30535488</pub-id><pub-id pub-id-type="pmcid">PMC6317660</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC11448557"/></element-citation></ref><ref id="bib155"><label>153</label><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>O.S.</given-names></name><etal/></person-group><article-title>Extract of pinus densiflora needles suppresses acute inflammation by regulating inflammatory mediators in raw264.7 macrophages and mice</article-title><source>Pharm. Biol.</source><volume>60</volume><issue>1</issue><year>2022</year><fpage>1148</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1080/13880209.2022.2079679</pub-id><pub-id pub-id-type="pmid">35695008</pub-id><pub-id pub-id-type="pmcid">PMC9196672</pub-id></element-citation></ref><ref id="bib156"><label>154</label><mixed-citation publication-type="other" id="sref156">S. Bazzi, E. El-Darzi, T. Mcdowell, et al., Defining genome-wide expression and phenotypic contextual cues in macrophages generated by granulocyte/macrophage colony-stimulating factor, macrophage colony-stimulating factor, and heat-killed mycobacteria., Front. Immunol. 82017) 1253, <pub-id pub-id-type="doi">10.3389/fimmu.2017.01253</pub-id>.<pub-id pub-id-type="pmcid">PMC5632758</pub-id><pub-id pub-id-type="pmid">29046677</pub-id></mixed-citation></ref><ref id="bib157"><label>155</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>Dalakas</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Alexopoulos</surname><given-names>H.</given-names></name><name name-style="western"><surname>Spaeth</surname><given-names>P.J.</given-names></name></person-group><article-title>Complement in neurological disorders and emerging complement-targeted therapeutics</article-title><source>Nat. Rev. Neurol.</source><volume>16</volume><issue>11</issue><year>2020</year><fpage>601</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1038/s41582-020-0400-0</pub-id><pub-id pub-id-type="pmid">33005040</pub-id><pub-id pub-id-type="pmcid">PMC7528717</pub-id></element-citation></ref><ref id="bib158"><label>156</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>Gather</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ihrig-Biedert</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kohlhas</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A specific, non-immune system-related isoform of the human inducible nitric oxide synthase is expressed during differentiation of human stem cells into various cell types</article-title><source>Cell Commun. Signal. : CCS</source><volume>20</volume><issue>1</issue><year>2022</year><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/s12964-022-00855-x</pub-id><pub-id pub-id-type="pmid">35392923</pub-id><pub-id pub-id-type="pmcid">PMC8991583</pub-id></element-citation></ref><ref id="bib159"><label>157</label><mixed-citation publication-type="other" id="sref159">B. Zhou, J. Li, R. Liu, L. Zhu, C. Peng, The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria., Front. Immunol. 132022) 879754, <pub-id pub-id-type="doi">10.3389/fimmu.2022.879754</pub-id>.<pub-id pub-id-type="pmcid">PMC9193815</pub-id><pub-id pub-id-type="pmid">35711438</pub-id></mixed-citation></ref><ref id="bib160"><label>158</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name name-style="western"><surname>Lekhraj</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lalezari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aguilan</surname><given-names>J.T.</given-names></name><etal/></person-group><article-title>Altered abundances of human immunoglobulin m and immunoglobulin g subclasses in alzheimer's disease frontal cortex</article-title><source>Sci. Rep.</source><volume>12</volume><issue>1</issue><year>2022</year><fpage>6934</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-10793-w</pub-id><pub-id pub-id-type="pmid">35484384</pub-id><pub-id pub-id-type="pmcid">PMC9050688</pub-id></element-citation></ref><ref id="bib161"><label>159</label><mixed-citation publication-type="other" id="sref161">X. Tong, Y. Zheng, Y. Li, Y. Xiong, D. Chen, Soluble ligands as drug targets for treatment of inflammatory bowel disease., Pharmacol. Ther. 2262021) 107859, <pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107859</pub-id>.<pub-id pub-id-type="pmid">33895184</pub-id></mixed-citation></ref><ref id="bib162"><label>160</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name name-style="western"><surname>Hassanshahi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ranjbar</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Perspectives on agmatine neurotransmission in acute and chronic stressrelated conditions</article-title><source>Mini Rev. Med. Chem.</source><volume>23</volume><issue>15</issue><year>2023</year><fpage>1560</fpage><lpage>1574</lpage><pub-id pub-id-type="doi">10.2174/1389557523666230125104753</pub-id><pub-id pub-id-type="pmid">36698237</pub-id></element-citation></ref><ref id="bib163"><label>161</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>Salminen</surname><given-names>A.</given-names></name></person-group><article-title>Clinical perspectives on the age-related increase of immunosuppressive activity</article-title><source>J. Mol. Med.</source><volume>100</volume><issue>5</issue><year>2022</year><fpage>697</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1007/s00109-022-02193-4</pub-id><pub-id pub-id-type="pmid">35384505</pub-id><pub-id pub-id-type="pmcid">PMC8985067</pub-id></element-citation></ref><ref id="bib164"><label>162</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name name-style="western"><surname>Dhoundiyal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name></person-group><article-title>Nanomedicines: impactful approaches for targeting pulmonary diseases</article-title><source>Pharm. Nanotechnol.</source><year>2023</year><pub-id pub-id-type="doi">10.2174/2211738511666230525151106</pub-id><pub-id pub-id-type="pmid">37231722</pub-id></element-citation></ref><ref id="bib165"><label>163</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name name-style="western"><surname>Quan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Current status and preventive strategies of chronic obstructive pulmonary disease in China: a literature review</article-title><source>J. Thorac. Dis.</source><volume>13</volume><issue>6</issue><year>2021</year><fpage>3865</fpage><lpage>3877</lpage><pub-id pub-id-type="doi">10.21037/jtd-20-2051</pub-id><pub-id pub-id-type="pmid">34277076</pub-id><pub-id pub-id-type="pmcid">PMC8264680</pub-id></element-citation></ref><ref id="bib166"><label>164</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name></person-group><article-title>Unique pharmacology, brain dysfunction, and therapeutic advancements for fentanyl misuse and abuse</article-title><source>Neurosci. Bull.</source><volume>38</volume><issue>11</issue><year>2022</year><fpage>1365</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1007/s12264-022-00872-3</pub-id><pub-id pub-id-type="pmid">35570233</pub-id><pub-id pub-id-type="pmcid">PMC9107910</pub-id></element-citation></ref><ref id="bib167"><label>165</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name name-style="western"><surname>Jose</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Soman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Thulaseedharan</surname><given-names>J.V.</given-names></name><etal/></person-group><article-title>Demographic and clinical characteristics of primary lung cancer patients in Kerala: analysis of data from six teaching centers</article-title><source>J. Fam. Med. Prim. Care</source><volume>12</volume><issue>10</issue><year>2023</year><fpage>2501</fpage><lpage>2506</lpage><pub-id pub-id-type="doi">10.4103/jfmpc.jfmpc_2176_22</pub-id><pub-id pub-id-type="pmcid">PMC10706524</pub-id><pub-id pub-id-type="pmid">38074238</pub-id></element-citation></ref><ref id="bib168"><label>166</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>Mbeje</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Ginindza</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jafta</surname><given-names>N.</given-names></name></person-group><article-title>Epidemiological study of risk factors for lung cancer in kwazulu-natal, South Africa</article-title><source>Int. J. Environ. Res. Publ. Health</source><volume>19</volume><issue>11</issue><year>2022</year><pub-id pub-id-type="doi">10.3390/ijerph19116752</pub-id><pub-id pub-id-type="pmcid">PMC9180813</pub-id><pub-id pub-id-type="pmid">35682333</pub-id></element-citation></ref><ref id="bib169"><label>167</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name name-style="western"><surname>Reynaert</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Vanfleteren</surname><given-names>L.E.G.W.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>T.N.</given-names></name></person-group><article-title>The age-rage axis and the pathophysiology of multimorbidity in copd</article-title><source>J. Clin. Med.</source><volume>12</volume><issue>10</issue><year>2023</year><pub-id pub-id-type="doi">10.3390/jcm12103366</pub-id><pub-id pub-id-type="pmcid">PMC10219583</pub-id><pub-id pub-id-type="pmid">37240472</pub-id></element-citation></ref><ref id="bib170"><label>168</label><element-citation publication-type="journal" id="sref170"><person-group person-group-type="author"><name name-style="western"><surname>Parris</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>O'Farrell</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Fong</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>I.A.</given-names></name></person-group><article-title>Chronic obstructive pulmonary disease (copd) and lung cancer: common pathways for pathogenesis</article-title><source>J. Thorac. Dis.</source><volume>11</volume><issue>Suppl 17</issue><year>2019</year><fpage>S2155</fpage><lpage>S2172</lpage><pub-id pub-id-type="doi">10.21037/jtd.2019.10.54</pub-id><pub-id pub-id-type="pmid">31737343</pub-id><pub-id pub-id-type="pmcid">PMC6831920</pub-id></element-citation></ref><ref id="bib171"><label>169</label><element-citation publication-type="journal" id="sref171"><person-group person-group-type="author"><name name-style="western"><surname>Faherty</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kenny</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cloonan</surname><given-names>S.M.</given-names></name></person-group><article-title>Iron and mitochondria in the susceptibility, pathogenesis and progression of copd</article-title><source>Clin. Sci.</source><volume>137</volume><issue>3</issue><year>2023</year><fpage>219</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1042/CS20210504</pub-id><pub-id pub-id-type="pmid">36729089</pub-id></element-citation></ref><ref id="bib172"><label>170</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name name-style="western"><surname>Uli&#324;ski</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kwiecie&#324;</surname><given-names>I.</given-names></name><name name-style="western"><surname>Domaga&#322;a-Kulawik</surname><given-names>J.</given-names></name></person-group><article-title>Lung cancer in the course of copd-emerging problems today</article-title><source>Cancers</source><volume>14</volume><issue>15</issue><year>2022</year><pub-id pub-id-type="doi">10.3390/cancers14153819</pub-id><pub-id pub-id-type="pmcid">PMC9367492</pub-id><pub-id pub-id-type="pmid">35954482</pub-id></element-citation></ref><ref id="bib173"><label>171</label><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Park</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Cancer development in patients with copd: a retrospective analysis of the national health insurance service-national sample cohort in korea</article-title><source>BMC Pulm. Med.</source><volume>20</volume><issue>1</issue><year>2020</year><fpage>170</fpage><pub-id pub-id-type="doi">10.1186/s12890-020-01194-8</pub-id><pub-id pub-id-type="pmid">32539764</pub-id><pub-id pub-id-type="pmcid">PMC7296952</pub-id></element-citation></ref><ref id="bib174"><label>172</label><mixed-citation publication-type="other" id="sref174">D. Majumder, R. Debnath, D. Maiti, Il-27 along with il-28b ameliorates the pulmonary redox impairment, inflammation and immunosuppression in benzo(a)pyrene induced lung cancer bearing mice., Life Sci. 2602020) 118384, <pub-id pub-id-type="doi">10.1016/j.lfs.2020.118384</pub-id>.<pub-id pub-id-type="pmid">32898529</pub-id></mixed-citation></ref><ref id="bib175"><label>173</label><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name name-style="western"><surname>Caramori</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ruggeri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mumby</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Molecular links between copd and lung cancer: new targets for drug discovery?</article-title><source>Expert Opin. Ther. Targets</source><volume>23</volume><issue>6</issue><year>2019</year><fpage>539</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1080/14728222.2019.1615884</pub-id><pub-id pub-id-type="pmid">31079559</pub-id></element-citation></ref><ref id="bib176"><label>174</label><element-citation publication-type="journal" id="sref176"><person-group person-group-type="author"><name name-style="western"><surname>Morrow</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Hersh</surname><given-names>C.P.</given-names></name><etal/></person-group><article-title>Dna methylation profiling in human lung tissue identifies genes associated with copd</article-title><source>Epigenetics</source><volume>11</volume><issue>10</issue><year>2016</year><fpage>730</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1080/15592294.2016.1226451</pub-id><pub-id pub-id-type="pmid">27564456</pub-id><pub-id pub-id-type="pmcid">PMC5094634</pub-id></element-citation></ref><ref id="bib177"><label>175</label><mixed-citation publication-type="other" id="sref177">H. Lee, C.C. Jose, S. Cuddapah, Epithelial-mesenchymal transition: insights into nickel-induced lung diseases., Semin. Cancer Biol. 762021) 99-109, <pub-id pub-id-type="doi">10.1016/j.semcancer.2021.05.020</pub-id>.<pub-id pub-id-type="pmcid">PMC8627926</pub-id><pub-id pub-id-type="pmid">34058338</pub-id></mixed-citation></ref><ref id="bib178"><label>176</label><element-citation publication-type="journal" id="sref178"><person-group person-group-type="author"><name name-style="western"><surname>Buttgereit</surname><given-names>F.</given-names></name><name name-style="western"><surname>Scheffold</surname><given-names>A.</given-names></name></person-group><article-title>Rapid glucocorticoid effects on immune cells</article-title><source>Steroids</source><volume>67</volume><issue>6</issue><year>2002</year><fpage>529</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">11960631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0039-128x(01)00171-4</pub-id></element-citation></ref><ref id="bib179"><label>177</label><mixed-citation publication-type="other" id="sref179">Y. &#231;olak, B.G. Nordestgaard, P. Lange, J. Vestbo, S. Afzal, Supernormal lung function and risk of copd: a contemporary population-based cohort study., EClinicalMedicine 372021) 100974, <pub-id pub-id-type="doi">10.1016/j.eclinm.2021.100974</pub-id>.<pub-id pub-id-type="pmcid">PMC8225980</pub-id><pub-id pub-id-type="pmid">34195585</pub-id></mixed-citation></ref><ref id="bib180"><label>178</label><element-citation publication-type="journal" id="sref180"><person-group person-group-type="author"><name name-style="western"><surname>Ilari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vitiello</surname><given-names>L.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Daily vegetables intake and response to copd rehabilitation. The role of oxidative stress, inflammation and dna damage</article-title><source>Nutrients</source><volume>13</volume><issue>8</issue><year>2021</year><pub-id pub-id-type="doi">10.3390/nu13082787</pub-id><pub-id pub-id-type="pmcid">PMC8398833</pub-id><pub-id pub-id-type="pmid">34444947</pub-id></element-citation></ref><ref id="bib181"><label>179</label><mixed-citation publication-type="other" id="sref181">M. Liu, Y. Huo, Y. Cheng, Mechanistic regulation of wnt pathway-related progression of chronic obstructive pulmonary disease airway lesions., Int. J. Chronic Obstr. Pulm. Dis. 182023) 871-880, <pub-id pub-id-type="doi">10.2147/COPD.S391487</pub-id>.<pub-id pub-id-type="pmcid">PMC10198175</pub-id><pub-id pub-id-type="pmid">37215745</pub-id></mixed-citation></ref><ref id="bib182"><label>180</label><mixed-citation publication-type="other" id="sref182">M.A. Ponce-Gallegos, A. Ram&#237;rez-Venegas, R. Falf&#225;n-Valencia, Th17 profile in copd exacerbations., Int. J. Chronic Obstr. Pulm. Dis. 122017) 1857-1865, <pub-id pub-id-type="doi">10.2147/COPD.S136592</pub-id>.<pub-id pub-id-type="pmcid">PMC5491572</pub-id><pub-id pub-id-type="pmid">28694696</pub-id></mixed-citation></ref><ref id="bib183"><label>181</label><element-citation publication-type="journal" id="sref183"><person-group person-group-type="author"><name name-style="western"><surname>Strait</surname><given-names>A.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Margaretten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yazdany</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goglin</surname><given-names>S.</given-names></name></person-group><article-title>Race, ethnicity, and disparities in rheumatology educational materials</article-title><source>Arthritis Care Res.</source><volume>74</volume><issue>9</issue><year>2022</year><fpage>1416</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1002/acr.24602</pub-id><pub-id pub-id-type="pmid">33768717</pub-id></element-citation></ref><ref id="bib184"><label>182</label><element-citation publication-type="journal" id="sref184"><person-group person-group-type="author"><name name-style="western"><surname>Wechsler</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Menzies-Gow</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brightling</surname><given-names>C.E.</given-names></name><etal/></person-group><article-title>Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (source): a randomised, placebo-controlled, phase 3 study</article-title><source>Lancet Respir. Med.</source><volume>10</volume><issue>7</issue><year>2022</year><fpage>650</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00537-3</pub-id><pub-id pub-id-type="pmid">35364018</pub-id></element-citation></ref><ref id="bib185"><label>183</label><element-citation publication-type="journal" id="sref185"><person-group person-group-type="author"><name name-style="western"><surname>Fedor</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Rubinstein</surname><given-names>A.</given-names></name></person-group><article-title>Effects of long-term low-dose corticosteroid therapy on humoral immunity</article-title><source>Ann. Allergy Asthma Immunol. : official publication of the American College of Allergy, Asthma, &amp; Immunology</source><volume>97</volume><issue>1</issue><year>2006</year><fpage>113</fpage><lpage>116</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1081-1206(10)61380-4</pub-id><pub-id pub-id-type="pmid">16892792</pub-id></element-citation></ref><ref id="bib186"><label>184</label><element-citation publication-type="journal" id="sref186"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gunturu</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Cardiotoxicity of immune checkpoint inhibitors</article-title><source>Curr. Oncol. Rep.</source><volume>23</volume><issue>7</issue><year>2021</year><fpage>79</fpage><pub-id pub-id-type="doi">10.1007/s11912-021-01070-6</pub-id><pub-id pub-id-type="pmid">33937956</pub-id><pub-id pub-id-type="pmcid">PMC8088903</pub-id></element-citation></ref><ref id="bib187"><label>185</label><element-citation publication-type="journal" id="sref187"><person-group person-group-type="author"><name name-style="western"><surname>Delaunay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cadranel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lusque</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients</article-title><source>Eur. Respir. J.</source><volume>50</volume><issue>2</issue><year>2017</year><pub-id pub-id-type="doi">10.1183/13993003.00050-2017</pub-id><pub-id pub-id-type="pmid">28798088</pub-id></element-citation></ref><ref id="bib188"><label>186</label><element-citation publication-type="journal" id="sref188"><person-group person-group-type="author"><name name-style="western"><surname>Berner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bomze</surname><given-names>D.</given-names></name><name name-style="western"><surname>Diem</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer</article-title><source>JAMA Oncol.</source><volume>5</volume><issue>7</issue><year>2019</year><fpage>1043</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2019.0402</pub-id><pub-id pub-id-type="pmid">31021392</pub-id><pub-id pub-id-type="pmcid">PMC6487908</pub-id></element-citation></ref><ref id="bib189"><label>187</label><element-citation publication-type="journal" id="sref189"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>[Investigation of lung cancer patients complicated with chronic obstructive pulmonary disease in thoracic surgical department]</article-title><source>Zhongguo fei ai za zhi = Chinese journal of lung cancer</source><volume>20</volume><issue>3</issue><year>2017</year><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.3779/j.issn.1009-3419.2017.03.04</pub-id><pub-id pub-id-type="pmid">28302218</pub-id><pub-id pub-id-type="pmcid">PMC5973300</pub-id></element-citation></ref><ref id="bib190"><label>188</label><element-citation publication-type="journal" id="sref190"><person-group person-group-type="author"><name name-style="western"><surname>De-Torres</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Mar&#237;n</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Casanova</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Identification of copd patients at high risk for lung cancer mortality using the copd-lucss-dlco</article-title><source>Chest</source><volume>149</volume><issue>4</issue><year>2016</year><fpage>936</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1378/chest.15-1868</pub-id><pub-id pub-id-type="pmid">26513409</pub-id></element-citation></ref><ref id="bib191"><label>189</label><mixed-citation publication-type="other" id="sref191">H. Whittaker, A. Rubino, H. M&#252;llerov&#225;, et al., Frequency and severity of exacerbations of copd associated with future risk of exacerbations and mortality: a uk routine health care data study., Int. J. Chronic Obstr. Pulm. Dis. 172022) 427-437, <pub-id pub-id-type="doi">10.2147/COPD.S346591</pub-id>.<pub-id pub-id-type="pmcid">PMC8901192</pub-id><pub-id pub-id-type="pmid">35264849</pub-id></mixed-citation></ref><ref id="bib192"><label>190</label><element-citation publication-type="journal" id="sref192"><person-group person-group-type="author"><name name-style="western"><surname>Carlier</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Detry</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lecocq</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The memory of airway epithelium damage in smokers and copd patients</article-title><source>Life Sci. Alliance</source><volume>7</volume><issue>3</issue><year>2024</year><pub-id pub-id-type="doi">10.26508/lsa.202302341</pub-id><pub-id pub-id-type="pmcid">PMC10756916</pub-id><pub-id pub-id-type="pmid">38158219</pub-id></element-citation></ref><ref id="bib193"><label>191</label><mixed-citation publication-type="other" id="sref193">A.G. Kaplan, Applying the wisdom of stepping down inhaled corticosteroids in patients with copd: a proposed algorithm for clinical practice., Int. J. Chronic Obstr. Pulm. Dis. 102015) 2535-2548, <pub-id pub-id-type="doi">10.2147/COPD.S93321</pub-id>.<pub-id pub-id-type="pmcid">PMC4664433</pub-id><pub-id pub-id-type="pmid">26648711</pub-id></mixed-citation></ref><ref id="bib194"><label>192</label><mixed-citation publication-type="other" id="sref194">J.L. Izquierdo, B.G. Cosio, The dose of inhaled corticosteroids in patients with copd: when less is better., Int. J. Chronic Obstr. Pulm. Dis. 132018) 3539-3547, <pub-id pub-id-type="doi">10.2147/COPD.S175047</pub-id>.<pub-id pub-id-type="pmcid">PMC6207269</pub-id><pub-id pub-id-type="pmid">30498343</pub-id></mixed-citation></ref><ref id="bib195"><label>193</label><element-citation publication-type="journal" id="sref195"><person-group person-group-type="author"><name name-style="western"><surname>Mathioudakis</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Bikov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Foden</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in copd</article-title><source>Eur. Respir. J.</source><volume>55</volume><issue>5</issue><year>2020</year><pub-id pub-id-type="doi">10.1183/13993003.02119-2019</pub-id><pub-id pub-id-type="pmid">32108044</pub-id></element-citation></ref><ref id="bib196"><label>194</label><element-citation publication-type="journal" id="sref196"><person-group person-group-type="author"><name name-style="western"><surname>Keir</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Contoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chalmers</surname><given-names>J.D.</given-names></name></person-group><article-title>Inhaled corticosteroids and the lung microbiome in copd</article-title><source>Biomedicines</source><volume>9</volume><issue>10</issue><year>2021</year><pub-id pub-id-type="doi">10.3390/biomedicines9101312</pub-id><pub-id pub-id-type="pmcid">PMC8533282</pub-id><pub-id pub-id-type="pmid">34680429</pub-id></element-citation></ref><ref id="bib197"><label>195</label><element-citation publication-type="journal" id="sref197"><person-group person-group-type="author"><name name-style="western"><surname>Marik</surname><given-names>P.E.</given-names></name></person-group><article-title>The role of glucocorticoids as adjunctive treatment for sepsis in the modern era</article-title><source>Lancet Respir. Med.</source><volume>6</volume><issue>10</issue><year>2018</year><fpage>793</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(18)30265-0</pub-id><pub-id pub-id-type="pmid">30006071</pub-id></element-citation></ref><ref id="bib198"><label>196</label><element-citation publication-type="journal" id="sref198"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Song</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Research progress on the anticancer activity of plant polysaccharides</article-title><source>Recent Pat. Anti-Cancer Drug Discov.</source><year>2023</year><pub-id pub-id-type="doi">10.2174/1574892819666230915103434</pub-id><pub-id pub-id-type="pmid">37724671</pub-id></element-citation></ref><ref id="bib199"><label>197</label><element-citation publication-type="journal" id="sref199"><person-group person-group-type="author"><name name-style="western"><surname>Laugesen</surname><given-names>K.</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Jorgensen</surname><given-names>J.O.L.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>I.</given-names></name></person-group><article-title>Prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood</article-title><source>Eur. J. Endocrinol.</source><volume>186</volume><issue>4</issue><year>2022</year><fpage>429</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1530/EJE-21-0846</pub-id><pub-id pub-id-type="pmid">35104239</pub-id><pub-id pub-id-type="pmcid">PMC8942335</pub-id></element-citation></ref><ref id="bib200"><label>198</label><mixed-citation publication-type="other" id="sref200">I. Veneziani, C. Alicata, L. Moretta, E. Maggi, Human toll-like receptor 8 (tlr8) in nk cells: implication for cancer immunotherapy., Immunol. Lett. 2612023) 13-16, <pub-id pub-id-type="doi">10.1016/j.imlet.2023.07.003</pub-id>.<pub-id pub-id-type="pmid">37451320</pub-id></mixed-citation></ref><ref id="bib201"><label>199</label><element-citation publication-type="journal" id="sref201"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Small-molecule pik-93 modulates the tumor microenvironment to improve immune checkpoint blockade response</article-title><source>Sci. Adv.</source><volume>9</volume><issue>14</issue><year>2023</year><object-id pub-id-type="publisher-id">eade9944</object-id><pub-id pub-id-type="doi">10.1126/sciadv.ade9944</pub-id><pub-id pub-id-type="pmcid">PMC10081850</pub-id><pub-id pub-id-type="pmid">37027467</pub-id></element-citation></ref><ref id="bib202"><label>200</label><element-citation publication-type="journal" id="sref202"><person-group person-group-type="author"><name name-style="western"><surname>Mayne</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bharol</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Perioperative outcomes and survival after preoperative immunotherapy for non-small cell lung cancer</article-title><source>Ann. Thorac. Surg.</source><volume>113</volume><issue>6</issue><year>2022</year><fpage>1811</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2021.06.058</pub-id><pub-id pub-id-type="pmid">34314692</pub-id></element-citation></ref><ref id="bib203"><label>201</label><element-citation publication-type="journal" id="sref203"><person-group person-group-type="author"><name name-style="western"><surname>Fuc&#224;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Poggi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors</article-title><source>ESMO Open</source><volume>4</volume><issue>1</issue><year>2019</year><fpage>e457</fpage><pub-id pub-id-type="doi">10.1136/esmoopen-2018-000457</pub-id><pub-id pub-id-type="pmcid">PMC6435242</pub-id><pub-id pub-id-type="pmid">30964126</pub-id></element-citation></ref><ref id="bib204"><label>202</label><element-citation publication-type="journal" id="sref204"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Lariviere</surname><given-names>M.</given-names></name><name name-style="western"><surname>Macduffie</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Use of glucocorticoids in patients with cancer: potential benefits, harms, and practical considerations for clinical practice</article-title><source>Pract. Radiat. Oncol.</source><volume>13</volume><issue>1</issue><year>2023</year><fpage>28</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.prro.2022.07.003</pub-id><pub-id pub-id-type="pmid">35917896</pub-id></element-citation></ref><ref id="bib205"><label>203</label><mixed-citation publication-type="other" id="sref205">H.T. Vechi, L.R. Maia, M.D.M. Alves, J.F. Rodrigues-Neto, Favorable outcome of covid-19 in a young woman with severe crohn's disease on regular use of adalimumab and prednisone: a case report., Rev. Inst. Med. Trop. Sao Paulo 622020) e102, <pub-id pub-id-type="doi">10.1590/S1678-9946202062102</pub-id>.<pub-id pub-id-type="pmcid">PMC7748034</pub-id><pub-id pub-id-type="pmid">33331521</pub-id></mixed-citation></ref><ref id="bib206"><label>204</label><element-citation publication-type="journal" id="sref206"><person-group person-group-type="author"><name name-style="western"><surname>Kagan</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Rothenberg</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rudensky</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Smale</surname><given-names>S.T.</given-names></name></person-group><article-title>Cold spring harbor laboratory 2022: emerging insights and viewpoints in immunology</article-title><source>Trends Immunol.</source><volume>44</volume><issue>4</issue><year>2023</year><fpage>248</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.it.2023.02.003</pub-id><pub-id pub-id-type="pmid">36907684</pub-id></element-citation></ref><ref id="bib207"><label>205</label><element-citation publication-type="journal" id="sref207"><person-group person-group-type="author"><name name-style="western"><surname>Yun</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Bazhenova</surname><given-names>L.</given-names></name></person-group><article-title>Management of toxicities associated with immune checkpoint inhibitors</article-title><source>Clin. Adv. Hematol. Oncol. : HO (Hum. Organ.)</source><volume>21</volume><issue>3</issue><year>2023</year><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">36867558</pub-id></element-citation></ref><ref id="bib208"><label>206</label><element-citation publication-type="journal" id="sref208"><person-group person-group-type="author"><name name-style="western"><surname>Nieder</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reigstad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Flat&#248;y</surname><given-names>L.</given-names></name><name name-style="western"><surname>Toll&#229;li</surname><given-names>T.</given-names></name></person-group><article-title>Initial experience after transition to immune checkpoint inhibitors in patients with non-small cell lung cancer treated in a rural healthcare region</article-title><source>Cureus J Med Sci</source><volume>12</volume><issue>2</issue><year>2020</year><object-id pub-id-type="publisher-id">e7030</object-id><pub-id pub-id-type="doi">10.7759/cureus.7030</pub-id><pub-id pub-id-type="pmcid">PMC7081957</pub-id><pub-id pub-id-type="pmid">32211263</pub-id></element-citation></ref><ref id="bib209"><label>207</label><element-citation publication-type="journal" id="sref209"><person-group person-group-type="author"><name name-style="western"><surname>Petrelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Signorelli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ghidini</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis</article-title><source>Cancers</source><volume>12</volume><issue>3</issue><year>2020</year><pub-id pub-id-type="doi">10.3390/cancers12030546</pub-id><pub-id pub-id-type="pmcid">PMC7139305</pub-id><pub-id pub-id-type="pmid">32120803</pub-id></element-citation></ref><ref id="bib210"><label>208</label><element-citation publication-type="journal" id="sref210"><person-group person-group-type="author"><name name-style="western"><surname>Ricciuti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dahlberg</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Adeni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sholl</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Nishino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Awad</surname><given-names>M.M.</given-names></name></person-group><article-title>Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications</article-title><source>J. Clin. Oncol. : official journal of the American Society of Clinical Oncology</source><volume>37</volume><issue>22</issue><year>2019</year><fpage>1927</fpage><lpage>1934</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.00189</pub-id><pub-id pub-id-type="pmid">31206316</pub-id></element-citation></ref><ref id="bib211"><label>209</label><element-citation publication-type="journal" id="sref211"><person-group person-group-type="author"><name name-style="western"><surname>Leo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Menger</surname><given-names>H.</given-names></name></person-group><article-title>[Exacerbations of chronic obstructive pulmonary disease - diagnostic approach, management and follow-up care]</article-title><source>Dtsch. Med. Wochenschr.</source><volume>144</volume><issue>1</issue><year>1946</year><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1055/a-0723-4172</pub-id><comment>2019</comment><pub-id pub-id-type="pmid">30602183</pub-id></element-citation></ref><ref id="bib212"><label>210</label><element-citation publication-type="journal" id="sref212"><person-group person-group-type="author"><name name-style="western"><surname>Powell</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Abreu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with nsclc and stable brain metastases: pooled analysis of keynote-021, -189, and -407</article-title><source>J. Thorac. Oncol. : official publication of the International Association for the Study of Lung Cancer</source><volume>16</volume><issue>11</issue><year>2021</year><fpage>1883</fpage><lpage>1892</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2021.06.020</pub-id><pub-id pub-id-type="pmid">34265431</pub-id></element-citation></ref><ref id="bib213"><label>211</label><mixed-citation publication-type="other" id="sref213">Y. Li, H. Fan, J. Ding, J. Xu, C. Liu, H. Wang, Microfluidic devices: the application in tme modeling and the potential in immunotherapy optimization., Front. Genet. 132022) 969723, <pub-id pub-id-type="doi">10.3389/fgene.2022.969723</pub-id>.<pub-id pub-id-type="pmcid">PMC9493116</pub-id><pub-id pub-id-type="pmid">36159996</pub-id></mixed-citation></ref><ref id="bib214"><label>212</label><element-citation publication-type="journal" id="sref214"><person-group person-group-type="author"><name name-style="western"><surname>Ikuta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ejima</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shimba</surname><given-names>A.</given-names></name></person-group><article-title>Control of immunity and allergy by steroid hormones</article-title><source>Allergol. Int. : official journal of the Japanese Society of Allergology</source><volume>71</volume><issue>4</issue><year>2022</year><fpage>432</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/j.alit.2022.07.006</pub-id><pub-id pub-id-type="pmid">35973911</pub-id></element-citation></ref><ref id="bib215"><label>213</label><mixed-citation publication-type="other" id="sref215">L. Zhao, X. Yang, Cross talk between natural killer t and dendritic cells and its impact on t cell responses in infections., Front. Immunol. 132022) 837767, <pub-id pub-id-type="doi">10.3389/fimmu.2022.837767</pub-id>.<pub-id pub-id-type="pmcid">PMC8850912</pub-id><pub-id pub-id-type="pmid">35185930</pub-id></mixed-citation></ref><ref id="bib216"><label>214</label><mixed-citation publication-type="other" id="sref216">L. de Lima Thomaz, G. Peron, J. Oliveira, L.C. Da Rosa, R. Thom&#233;, L. Verinaud, The impact of metabolic reprogramming on dendritic cell function., Int. Immunopharm. 632018) 84-93, <pub-id pub-id-type="doi">10.1016/j.intimp.2018.07.031</pub-id>.<pub-id pub-id-type="pmid">30075432</pub-id></mixed-citation></ref><ref id="bib217"><label>215</label><mixed-citation publication-type="other" id="sref217">A. Petrasca, D.G. Doherty, Human v&#948;2(+) &#947;&#948; t cells differentially induce maturation, cytokine production, and alloreactive t cell stimulation by dendritic cells and b cells., Front. Immunol. 52014) 650, <pub-id pub-id-type="doi">10.3389/fimmu.2014.00650</pub-id>.<pub-id pub-id-type="pmcid">PMC4271703</pub-id><pub-id pub-id-type="pmid">25566261</pub-id></mixed-citation></ref><ref id="bib218"><label>216</label><element-citation publication-type="journal" id="sref218"><person-group person-group-type="author"><name name-style="western"><surname>Xiu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>Ag490 reverses phenotypic alteration of dendritic cells by bladder cancer cells</article-title><source>Oncol. Lett.</source><volume>16</volume><issue>3</issue><year>2018</year><fpage>2851</fpage><lpage>2856</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.9028</pub-id><pub-id pub-id-type="pmid">30127871</pub-id><pub-id pub-id-type="pmcid">PMC6096164</pub-id></element-citation></ref><ref id="bib219"><label>217</label><mixed-citation publication-type="other" id="sref219">Q. Bao, Q. Huang, Y. Chen, et al., Tumor-derived extracellular vesicles regulate cancer progression in the tumor microenvironment., Front. Mol. Biosci. 82021) 796385, <pub-id pub-id-type="doi">10.3389/fmolb.2021.796385</pub-id>.<pub-id pub-id-type="pmcid">PMC8764126</pub-id><pub-id pub-id-type="pmid">35059436</pub-id></mixed-citation></ref><ref id="bib220"><label>218</label><element-citation publication-type="journal" id="sref220"><person-group person-group-type="author"><name name-style="western"><surname>Arziman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanriverdi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kucukvardar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Citil</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yildiz</surname><given-names>A.</given-names></name></person-group><article-title>Salicylidene acylhydrazides attenuate survival of sh-sy5y neuroblastoma cells through affecting mitotic regulator speedy/ringo and erk/mapk-pi3k/akt signaling</article-title><source>Med. Oncol.</source><volume>37</volume><issue>8</issue><year>2020</year><fpage>65</fpage><pub-id pub-id-type="doi">10.1007/s12032-020-01391-9</pub-id><pub-id pub-id-type="pmid">32691165</pub-id></element-citation></ref><ref id="bib221"><label>219</label><mixed-citation publication-type="other" id="sref221">&#201;.S. Vanamee, D.L. Faustman, The benefits of clustering in tnf receptor superfamily signaling., Front. Immunol. 142023) 1225704, <pub-id pub-id-type="doi">10.3389/fimmu.2023.1225704</pub-id>.<pub-id pub-id-type="pmcid">PMC10469783</pub-id><pub-id pub-id-type="pmid">37662920</pub-id></mixed-citation></ref><ref id="bib222"><label>220</label><element-citation publication-type="journal" id="sref222"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Emerging role of ubiquitination/deubiquitination modification of pd-1/pd-l1 in cancer immunotherapy</article-title><source>Genes Dis</source><volume>10</volume><issue>3</issue><year>2023</year><fpage>848</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1016/j.gendis.2022.01.002</pub-id><pub-id pub-id-type="pmid">37396527</pub-id><pub-id pub-id-type="pmcid">PMC10308071</pub-id></element-citation></ref><ref id="bib223"><label>221</label><element-citation publication-type="journal" id="sref223"><person-group person-group-type="author"><name name-style="western"><surname>Gubser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pascoe</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Gitr activation ex vivo impairs cd8 t cell function in people with hiv on antiretroviral therapy</article-title><source>iScience</source><volume>26</volume><issue>11</issue><year>2023</year><object-id pub-id-type="publisher-id">108165</object-id><pub-id pub-id-type="doi">10.1016/j.isci.2023.108165</pub-id><pub-id pub-id-type="pmcid">PMC10660494</pub-id><pub-id pub-id-type="pmid">38026168</pub-id></element-citation></ref><ref id="bib224"><label>222</label><element-citation publication-type="journal" id="sref224"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Atypical tnf-tnfr superfamily binding interface in the gitr-gitrl complex for t cell activation</article-title><source>Cell Rep.</source><volume>36</volume><issue>12</issue><year>2021</year><object-id pub-id-type="publisher-id">109734</object-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109734</pub-id><pub-id pub-id-type="pmid">34551288</pub-id></element-citation></ref><ref id="bib225"><label>223</label><mixed-citation publication-type="other" id="sref225">K. Kucka, H. Wajant, Receptor oligomerization and its relevance for signaling by receptors of the tumor necrosis factor receptor superfamily., Front. Cell Dev. Biol. 82020) 615141, <pub-id pub-id-type="doi">10.3389/fcell.2020.615141</pub-id>.<pub-id pub-id-type="pmcid">PMC7905041</pub-id><pub-id pub-id-type="pmid">33644033</pub-id></mixed-citation></ref><ref id="bib226"><label>224</label><element-citation publication-type="journal" id="sref226"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>F.</given-names></name></person-group><article-title>Development of a fully human anti-gitr antibody with potent antitumor activity using h2l2 mice</article-title><source>FEBS Open Bio</source><volume>12</volume><issue>8</issue><year>2022</year><fpage>1542</fpage><lpage>1557</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.13451</pub-id><pub-id pub-id-type="pmcid">PMC9340783</pub-id><pub-id pub-id-type="pmid">35674216</pub-id></element-citation></ref><ref id="bib227"><label>225</label><element-citation publication-type="journal" id="sref227"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>H3k4 trimethylation regulates cancer immunity: a promising therapeutic target in combination with immunotherapy</article-title><source>J. Immunother. Cancer</source><volume>11</volume><issue>8</issue><year>2023</year><pub-id pub-id-type="doi">10.1136/jitc-2022-005693</pub-id><pub-id pub-id-type="pmcid">PMC10414074</pub-id><pub-id pub-id-type="pmid">37553181</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>